<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">MAbs</journal-id><journal-id journal-id-type="iso-abbrev">MAbs</journal-id><journal-id journal-id-type="pmc-domain-id">934</journal-id><journal-id journal-id-type="pmc-domain">mabs</journal-id><journal-title-group><journal-title>mAbs</journal-title></journal-title-group><issn pub-type="ppub">1942-0862</issn><issn pub-type="epub">1942-0870</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12128664</article-id><article-id pub-id-type="pmcid-ver">PMC12128664.1</article-id><article-id pub-id-type="pmcaid">12128664</article-id><article-id pub-id-type="pmcaiid">12128664</article-id><article-id pub-id-type="pmid">40447562</article-id><article-id pub-id-type="doi">10.1080/19420862.2025.2512217</article-id><article-id pub-id-type="publisher-id">2512217</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Report</subject></subj-group></article-categories><title-group><article-title>Does one model fit all mAbs? An evaluation of population pharmacokinetic models</article-title><alt-title alt-title-type="left-running-head">S. P. H. VAN DEN BERG ET AL.</alt-title><alt-title alt-title-type="right-running-head">MABS</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-2181-094X</contrib-id><name name-style="western"><surname>van den Berg</surname><given-names initials="SPH">Stefan P. H.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Adolfsen</surname><given-names initials="PEA">Philine E. A.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3076-8435</contrib-id><name name-style="western"><surname>Dorlo</surname><given-names initials="TPC">Thomas P.C.</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rispens</surname><given-names initials="T">Theo</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>a</label><institution-wrap><institution>Sanquin Research Amsterdam</institution></institution-wrap>, <city>Amsterdam</city>, <country>The Netherlands</country></aff><aff id="aff0002"><label>b</label><institution-wrap><institution>Amsterdam Institute for Infection and Immunity</institution></institution-wrap>, <city>Amsterdam</city>, <country>The Netherlands</country></aff><aff id="aff0003"><label>c</label>Molecular Cell Biology and Immunology, <institution-wrap><institution>Amsterdam UMC location Vrije Universiteit Amsterdam</institution></institution-wrap>, <city>Amsterdam</city>, <country>The Netherlands</country></aff><aff id="aff0004"><label>d</label>Department of Pharmacy, <institution-wrap><institution>Uppsala University</institution></institution-wrap>, <city>Uppsala</city>, <country>Sweden</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Theo Rispens <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:t.rispens@sanquin.nl">t.rispens@sanquin.nl</email> Amsterdam UMC Location Vrije Universiteit Amsterdam, Molecular Cell Biology and Immunology, <addr-line>Sanquin Research, Plesmanlaan 125</addr-line>, <city>Amsterdam</city>, <state>CX</state><postal-code>1066</postal-code>, <country>The Netherlands</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>5</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>17</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">477326</issue-id><elocation-id seq="54">2512217</elocation-id><pub-history><event event-type="pmc-release"><date><day>30</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-03 10:25:14.500"><day>03</day><month>06</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>31</day><month>5</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>31</day><month>5</month><year>2025</year></date></event><event event-type="received"><date><day>17</day><month>3</month><year>2025</year></date></event><event event-type="revised"><date><day>20</day><month>5</month><year>2025</year></date></event><event event-type="accepted"><date><day>21</day><month>5</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="KMAB_17_2512217.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="KMAB_17_2512217.pdf"/><abstract><title>ABSTRACT</title><p>Antibodies are extensively used in treating various diseases, with over 100 canonical monoclonal antibodies (mAbs) approved. Population pharmacokinetic (PK) models are typically developed for each individual mAb, despite their similarities in size, shape, and susceptibility to lysosomal degradation. However, sparse datasets with limited PK information pose challenges in deriving accurate parameter estimates. Here, we provide a comprehensive overview of 160 published models of 69 mAbs, administered either intravenously or subcutaneously, examining their structural, statistical, and covariate components. Median estimates for the base parameters are linear clearance (0.22&#8201;L/d), central volume (3.42&#8201;L), peripheral volume (2.68&#8201;L), intercompartmental clearance (0.54&#8201;L/d), absorption rate (0.25&#8201;L/d), and bioavailability (69%). Using these to simulate a &#8216;generic&#8217; mAb results in plausible kinetics with a terminal half-life of 21&#8201;ds. We demonstrated that the median linear clearance was 26% lower in models that included nonlinear target-mediated kinetics, when compared to linear models (0.18 vs. 0.25&#8201;L/d). For chimeric mAbs median linear clearance was 50% higher compared to fully human and humanized mAbs. Variability in PK parameter estimates across models was comparable to the inter-individual variability, which have consistently shown to be large for mAbs PK (e.g. 55% vs. 43% for clearance and 25% vs. 30% for central volume, respectively). Our meta-analysis suggests that a priori parameter estimates derived from the large body of existing pharmacokinetic models for mAbs are representative for many mAbs and can facilitate the design of new and/or more complex pharmacokinetic models or assist in dose optimization models.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Biologics</kwd><kwd>generic model</kwd><kwd>linear clearance</kwd><kwd>meta-analysis</kwd><kwd>models</kwd><kwd>monoclonal antibodies</kwd><kwd>population pharmacokinetics</kwd><kwd>target-mediated drug disposition</kwd></kwd-group><support-group><funding-group><funding-statement>The author(s) reported there is no funding associated with the work featured in this article.</funding-statement></funding-group></support-group><counts><fig-count count="5"/><table-count count="2"/><ref-count count="194"/><page-count count="16"/><word-count count="6741"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><p>Antibodies and their derivatives play a crucial role in addressing various therapeutic areas, including oncology, hematology, infectious diseases, and autoimmune conditions. Various antibody formats have been developed or are in development, encompassing canonical full-length monoclonal antibodies (mAbs) consisting of an Fc and two Fab arms, Fc or Fab fragments, antibody&#8211;drug conjugates, and many more.<sup><xref rid="cit0001" ref-type="bibr">1</xref></sup> Of the four human immunoglobulin G (IgG) subclasses, IgG1, IgG2, and IgG4 are predominantly used as therapeutics due to their favorable half-life.<sup><xref rid="cit0002" ref-type="bibr">2</xref></sup> Up to and including June 2024, a total of 109 canonical therapeutic mAbs have been approved for treatment.<sup><xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0004" ref-type="bibr">4</xref></sup></p><p>The main route of antibody clearance is via nonspecific pinocytosis followed by intracellular proteolysis, which typically follows linear kinetics. The IgG molecules are taken up into endosomes, where IgG is engaged with the neonatal fragment crystallizable receptor (FcRn) under acidic conditions. The binding of IgG to the FcRn prevents them from lysosomal degradation, as the complexes return to the cell surface via the recycling endosome, where the IgG is released from the FcRn at the physiological pH. The salvage of IgG from degradation contributes to their long half-life. Other routes can also substantially contribute toward mAb elimination, such as target-mediated drug disposition (TMDD) and immunogenicity. TMDD occurs via binding and internalization of the drug-target complex, which can be modeled if the target concentration and turnover is quantified, although it is often simplified. Development of anti-drug antibodies (ADA) can cause additional drug clearance, lowered drug exposure, and consequently loss of response to treatment.</p><p>Although various modeling methods exist to capture pharmacokinetics (PK), population PK models are favored for their ability to account for nonlinear mechanisms and inter-individual variability (IIV).<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> Typically, PK parameters are estimated for each mAb individually. These estimates of parameters and related covariates of mAb models have been summarized previously.<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup> The overview suggested that most mAbs exhibit similar clearance (<italic toggle="yes">CL</italic>), volume of distribution in the central (<italic toggle="yes">V</italic><sub>C</sub>) and peripheral (<italic toggle="yes">V</italic><sub>P</sub>) compartment, and inter-compartmental clearance (<italic toggle="yes">Q</italic>), due to the minimal structural differences among mAbs. Several reviews have examined the covariates associated with mAb PK, with reported covariates related to general IgG homeostasis being body weight, albumin, and sex, while others were target- and disease-specific, e.g., target load, disease activity, tumor size, ADA, biomarkers like C-reactive protein.<sup><xref rid="cit0007" ref-type="bibr">7&#8211;9</xref></sup> Even accounting for covariates in mAb models in oncology, 75&#8211;80% of IIV was left unexplained.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup></p><p>Due to limitations like small patient populations and sparse datasets with limited sample sizes, it may be challenging to derive sufficient parameter estimate precision or even parameter identifiability. Moreover, for more complex models incorporating nonlinear effects such as TMDD, it can be challenging to accurately estimate all parameters. To address these challenges, we propose leveraging a generic model built upon data from numerous existing models, rather than relying on small, separate studies. A comprehensive model could significantly enhance more complex PK and pharmacodynamic modeling. Furthermore, increased efforts in dose optimization and individualization highlight the potential benefits of such a generic model in aiding these processes.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> A generic model for clotting factor VIII has demonstrated its ability to accurately predict individual PK.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup></p><p>Here, we examined previously published population PK models for canonical mAbs that have received market approval. The aim is to provide a comprehensive overview and analyze the variability observed in PK parameter estimates across models. We explored the parameter estimates for each component of the model: structural, statistical, and covariate. Additionally, we examined how differences in model structures affect these estimates, considering factors like nonlinearity, absorption kinetics, and mAb characteristics such as IgG type and chimeric content.</p></sec><sec disp-level="1" id="s0002"><title>Methods</title><sec disp-level="2" id="s0002-s2001"><title>PK models acquisition</title><p>The IMGT/mAb-DB database was queried for canonical mAbs, with only complete immunoglobulin G of every subclass, which were approved for marketing (IMGT query; IMGT Receptor Type&#8201;=&#8201;IG, IG class and subclass&#8201;=&#8201;any, IG format&#8201;=&#8201;None, Fused with&#8201;=&#8201;None, Radiolabelled with&#8201;=&#8201;None, Conjugated with&#8201;=&#8201;None).<sup><xref rid="cit0003" ref-type="bibr">3</xref></sup></p><p>Subsequently, the following query was done using PubMed<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> selecting each mAb collected from the IMGT/mAb-DB database:<disp-formula-group><disp-formula id="um0001"><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_UM0001.jpg"/><mml:math id="MATH0001"><mml:mrow><mml:mi mathvariant="normal">query</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="normal">abciximab</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">OR</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">adalimumab</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">OR</mml:mi><mml:mo>&#8901;</mml:mo><mml:mo>&#8901;</mml:mo><mml:mo>&#8901;</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mtext>&#160;</mml:mtext><mml:mrow><mml:mi mathvariant="normal">AND</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">population</mml:mi></mml:mrow><mml:mtext mathcolor="red">\break</mml:mtext><mml:mrow><mml:mi mathvariant="normal">AND</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi mathvariant="normal">pharmacokinetic</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">OR</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">pharmacokinetics</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:math></alternatives></disp-formula></disp-formula-group></p><p>Only peer-reviewed scientific articles reporting PK models from human studies were selected from the results. Studies that included noncompartmental analysis or reused existing models without estimating new PK parameters were excluded. We also included relevant papers identified through references cited in the selected studies. The selected papers were examined further and excluded if one of the following criteria was met: 1) mAbs were engineered for enhanced engagement with the FcRn or if the target was the FcRn receptor; 2) physiologically based PK or non-population models were reported; 3) administration was not intravenous (i.v.) or subcutaneous (s.c.); 4) non two-compartmental models were reported; 5) no linear clearance (only nonlinear elimination) was observed; 6) more than two of the base PK parameters (<italic toggle="yes">CL</italic>, <italic toggle="yes">V</italic><sub><italic toggle="yes">C</italic></sub>, <italic toggle="yes">V</italic><sub><italic toggle="yes">P</italic></sub>, <italic toggle="yes">Q)</italic> were fixed instead of estimated; 7) pediatric population models were reported; 8) bioavailability after s.c. administration was fixed to 100% absorption; 9) essential details about the model development or PK estimates were missing. All these papers were inspected, and their final PK model with other relevant data was extracted for further use. If no final model was provided, the base model estimates were utilized. In cases where both final and base models were reported, IIV were collected from both. We systematically gathered parameter estimates of structural, statistical, and covariate models. Covariate effects, functions, and related reference values were documented, as were relevant patient information, such as the patient group or disease, if healthy individuals were included, the number of samples and individuals, and specifics regarding nonlinear elimination or time-dependent parameters. Attention was given whether parameters were estimated or fixed.</p></sec><sec disp-level="2" id="s0002-s2002"><title>Data analysis</title><p>Data management, analysis, and visualization was done in R (Version 4.2.1) using RStudio (Version 2023.09.1). For each PK parameter, estimates were analyzed using the median and interquartile range (IQR). Estimates were used as reported in the publications without normalization to a reference covariate value. To support this methodology, we compared the estimates of models, including weight as a covariate, before and after normalizing to a reference weight of 70&#8201;kg. The assumption of a lognormal distribution of estimates was evaluated and is applied throughout this study.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> To address the bioavailability parameter, a logit transformation was applied. Variability in parameter estimates across models was expressed as the percent coefficient of variation (%CV) in the log-domain. PK models with time-dependent clearance, described using a sigmoid inhibition model (Hill-type function), were characterized by their baseline clearance, defined as the clearance at time infinity.</p><p>Estimates of PK parameters (<italic toggle="yes">CL</italic>, <italic toggle="yes">V</italic><sub><italic toggle="yes">C</italic></sub>, <italic toggle="yes">V</italic><sub><italic toggle="yes">P</italic></sub>, <italic toggle="yes">Q</italic>) were compared between model or mAb attributes using Wilcoxon rank tests. The former included comparisons based on the presence of nonlinear kinetics, administration route, or the detection method of the mAb, using all models, while the latter included comparisons with respect to mAb subclass or origin, based on the median estimate for each individual mAb. The relationship between patient counts and the z-score of a parameter estimate (the number of standard deviations away from the mean) was assessed using Spearman&#8217;s rank-order correlation.</p><p>IIV was examined by the CV for both base and final models. When the model was reported without any covariates, it was labeled as base model; otherwise, it was a final model. Given that the IIV of PK parameters was assumed to follow the log-normal distribution, the CV was (re)calculated in the log-domain (Supplementary Section M1). Residual unexplained variability (RUV) was examined by the CV of the proportional error either as reported or calculated from the reported variance or standard deviation. Errors were ignored if only estimates were presented without units or specified metrics. An additive error on log-transformed data is equivalent to a proportional error on the original scale.</p><p>We evaluated the frequency with which each covariate was included across models. To assess the effects of weight and albumin specifically, only models applying normalized power functions (i.e., allometric scaling) were considered. Covariate effects were summarized using the median and interquartile range (IQR). The covariate effect of sex was calculated with female as the reference value (Supplementary Section M2). To assess confounding covariates, the effect of sex was characterized in models with or without size descriptors on the same parameter. Vice versa, the allometric scaling coefficients of weight were characterized in models with or without sex as a covariate.</p></sec><sec disp-level="2" id="s0002-s2003"><title>Generic model simulation</title><p>Simulations of generic and reported population PK models were performed to illustrate the concept of a generic model. Nonlinear mixed-effects modeling software package NONMEM&#174; (Version 7.5.0) was used. The generic model was constructed as a two-compartment model with an absorption depot and fixing all parameters, by using the median values of all structural parameter estimates (<italic toggle="yes">CL</italic>, <italic toggle="yes">V</italic><sub>C</sub>, <italic toggle="yes">V</italic><sub>P</sub>, <italic toggle="yes">Q</italic>, <italic toggle="yes">k</italic><sub>a</sub>, <italic toggle="yes">F</italic>) and statistical parameter estimates (<italic toggle="yes">&#969;</italic><sup><italic toggle="yes">2</italic></sup><sub><italic toggle="yes">CL</italic></sub>, <italic toggle="yes">&#969;</italic><sup><italic toggle="yes">2</italic></sup><sub><italic toggle="yes">Vc</italic></sub>, <italic toggle="yes">&#969;</italic><sup><italic toggle="yes">2</italic></sup><sub><italic toggle="yes">k</italic>a</sub>) of all included population PK models in our analysis. No RUV or covariates were introduced. A simulation was conducted with 500 individuals following a 100&#8201;mg s.c. or i.v. drug administration. Individual parameters were derived using the typical parameter values multiplied by an exponential function of individual random effects, which were sampled with a mean of 0 and variance <italic toggle="yes">&#969;</italic><sup><italic toggle="yes">2</italic></sup>. The concentrations were determined (median, 5<sup>th</sup> and 95<sup>th</sup> quantiles) to contrast the generic model with all i.v. or i.v./s.c. models. The second simulation was performed likewise, using the structural typical parameter estimates as published, without IIV, and ran only once for the typical individual of each model. More details and the NONMEM code can be found in the supplementary material (Supplementary Section M5).</p></sec></sec><sec disp-level="1" id="s0003"><title>Results</title><sec disp-level="2" id="s0003-s2001"><title>Structural model</title><sec disp-level="3" id="s0003-s2001-s3001"><title>PK model collection</title><p>The full dataset consisted of 303 models, which after exclusion of one-compartment and pediatric models, s.c. models without bioavailability estimate, as well as an Fc-modified mAb with altered FcRn binding, resulted in 160 two-compartment population PK models of 69 different mAbs (<xref rid="f0001" ref-type="fig">Figure 1a,b</xref>; Supplementary Table S1). The largest number of models was available for rituximab (n&#8201;=&#8201;12) and infliximab (n&#8201;=&#8201;9), while 29 mAbs had only one model. Characteristics of the collected dataset were presented by all individual models or by grouping them by mAb (<xref rid="t0001" ref-type="table">Table 1</xref>). The full dataset is available online.
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>(a) Flow diagram of exclusion of population pharmacokinetic (PK) studies. Models that not had two compartments were excluded. Models that fixed 100% bioavailability after s.c. administration due to lack of i.v. data were excluded. Models that were fit on pediatric populations were excluded. Models of mAbs with increased binding to the neonatal Fc receptor (FcRn+) were excluded. (b) Overview of a two-compartment population PK model. (c) Distribution of base PK parameter estimates across population PK models visualized by violin and boxplots showing the interquartile range, with individual model values represented by dots. All models (<italic toggle="yes">n</italic>=160) with either only intravenous (i.v.) or both i.v. and subcutaneous (s.c.) administration are shown. (d) Absorption-related parameters in models (<italic toggle="yes">n</italic>=52) with both i.v. and s.c. administration. Vc = central volume of distribution, Vp = peripheral volume, CL = clearance, Q = intercompartmental clearance, ka = absorption rate, F = bioavailability.</p></caption><alt-text>A flow diagram starting with 220 models of 84 unique monoclonal antibodies, resulted after exclusion in 160 models of 69 unique monoclonal antibodies. The figures show a log-normal distribution of estimates for the PK parameters.</alt-text><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0001_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0001_PB.jpg"/></alternatives></fig><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Characteristics by model or monoclonal antibody.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">By model<break/>(<italic toggle="yes">n</italic> = 160)</th><th align="center" colspan="1" rowspan="1">By mAb<break/>(<italic toggle="yes">n</italic> = 69)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Group</td><td align="center" colspan="1" rowspan="1">Count (%)</td><td align="center" colspan="1" rowspan="1">Count (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nonlinear elimination</td><td align="center" colspan="1" rowspan="1">76 (47.5)</td><td align="center" colspan="1" rowspan="1">39 (56.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Time-dependent clearance</td><td align="center" colspan="1" rowspan="1">31 (19.4)</td><td align="center" colspan="1" rowspan="1">16 (23.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Healthy donors included</td><td align="center" colspan="1" rowspan="1">37 (23.1)</td><td align="center" colspan="1" rowspan="1">26 (37.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Subclass</italic></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">IgG1</td><td align="center" colspan="1" rowspan="1">115 (71.9)</td><td align="center" colspan="1" rowspan="1">47 (68.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">IgG2</td><td align="center" colspan="1" rowspan="1">14 (8.8)</td><td align="center" colspan="1" rowspan="1">6 (8.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">IgG4</td><td align="center" colspan="1" rowspan="1">29 (18.1)</td><td align="center" colspan="1" rowspan="1">15 (21.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">IgG2/4</td><td align="center" colspan="1" rowspan="1">2 (1.2)</td><td align="center" colspan="1" rowspan="1">1 (1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Origin</italic></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Chimeric</td><td align="center" colspan="1" rowspan="1">32 (20.0)</td><td align="center" colspan="1" rowspan="1">8 (11.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Humanized</td><td align="center" colspan="1" rowspan="1">56 (35.0)</td><td align="center" colspan="1" rowspan="1">25 (36.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fully human</td><td align="center" colspan="1" rowspan="1">72 (45.0)</td><td align="center" colspan="1" rowspan="1">36 (52.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Administration Route*</italic></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">i.v.</td><td align="center" colspan="1" rowspan="1">108 (67.5)</td><td align="center" colspan="1" rowspan="1">39 (56.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">s.c.</td><td align="center" colspan="1" rowspan="1">1 (0.6)</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">i.v./s.c.</td><td align="center" colspan="1" rowspan="1">51 (31.9)</td><td align="center" colspan="1" rowspan="1">30 (43.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Included covariate</italic></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Size descriptors</td><td align="center" colspan="1" rowspan="1">135 (84.4)</td><td align="center" colspan="1" rowspan="1">52 (75.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="center" colspan="1" rowspan="1">61 (38.1)</td><td align="center" colspan="1" rowspan="1">18 (26.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Albumin</td><td align="center" colspan="1" rowspan="1">68 (42.5)</td><td align="center" colspan="1" rowspan="1">20 (29)</td></tr><tr><td align="left" colspan="1" rowspan="1">ADA</td><td align="center" colspan="1" rowspan="1">26 (16.2)</td><td align="center" colspan="1" rowspan="1">13 (18.8)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p>Characteristics of the dataset with collected PK models of mAbs, as counted for models, or grouped by mAb. A mAb was considered for a given characteristic if it was present in at least one model for a particular mAb. Time-dependent clearance could be implemented as an effect on clearance, a second linear clearance or nonlinear kinetics. Only the most common covariates were included in the analysis. IgG = immunoglobulin G, mAb = monoclonal antibody, i.v. = intravenous, s.c. = subcutaneous, ADA = anti-drug antibodies. Size descriptors include weight, lean body mass, body mass index, fat-free mass and body surface area.</p></fn><fn id="tfn0002"><p>*If a mAb had either i.v. or s.c. and also i.v./s.c. models, it was counted as i.v./s.c.</p></fn></table-wrap-foot></table-wrap></p></sec><sec disp-level="3" id="s0003-s2001-s3002"><title>Structural PK estimates</title><p>First, we examined the estimates in the structural PK parameters across models (<xref rid="f0001" ref-type="fig">Figure 1c,d</xref>). The median (IQR) values of PK parameters were: <italic toggle="yes">CL</italic>&#8201;=&#8201;0.22 (0.17; 0.29) L/d, <italic toggle="yes">V</italic><sub>C</sub>&#8201;=&#8201;3.42 (2.96; 3.99) L, <italic toggle="yes">V</italic><sub>P</sub>&#8201;=&#8201;2.68 (2.09; 3.54) L, and <italic toggle="yes">Q</italic>&#8201;=&#8201;0.54 (0.36; 0.84) L/d. In addition, for models incorporating s.c. administration, median (IQR) estimates for absorption rate (<italic toggle="yes">k</italic><sub>a</sub>)&#8201;=&#8201;0.25 (0.18; 0.29) L/d, and bioavailability (<italic toggle="yes">F</italic>)&#8201;=&#8201;69 (61; 77) %. We confirmed that omitting normalization of estimates to a common weight (e.g., 70&#8201;kg) did not significantly change the median parameter estimates (Figure S1A). Furthermore, mAbs are primarily measured using an enzyme-linked immunosorbent assay or electrochemiluminescence, with both techniques yielding comparable estimates (Figure S1B).</p><p>Variability (%CV) between models in population estimates for <italic toggle="yes">CL</italic> and <italic toggle="yes">Q</italic> was 54.6% and 108%, respectively. Conversely, the <italic toggle="yes">V</italic><sub>C</sub> exhibited the least variability at 25%, indicating a more consistent size of central compartment across models. The peripheral volume demonstrated a threefold higher variability (73.9%) compared to the central volume. The variability in s.c. absorption-related parameters, <italic toggle="yes">k</italic><sub><italic toggle="yes">a</italic></sub> and <italic toggle="yes">F</italic>, was 34% and 61%, respectively.</p><p>To investigate whether variability in parameter estimates might be partially explained by parameter compensation, we examined the association between <italic toggle="yes">CL</italic>, <italic toggle="yes">V</italic><sub>C</sub>, <italic toggle="yes">V</italic><sub>P</sub>, and <italic toggle="yes">Q</italic>. Analysis revealed significant Spearman relationships between all pairs except of <italic toggle="yes">V</italic><sub>C</sub><italic toggle="yes">-Q</italic> (Figure S2A). This effect may be attributed to weight. After normalizing the PK estimates, correlations were observed only for <italic toggle="yes">V</italic><sub>C</sub><italic toggle="yes">-V</italic><sub>P</sub> (rho&#8201;=&#8201;0.27, p&#8201;=&#8201;0.0033; Figure S2B) and <italic toggle="yes">V</italic><sub>P</sub><italic toggle="yes">-Q</italic> (rho&#8201;=&#8201;0.33, p&#8201;=&#8201;0.0003). To assess whether inclusion of a s.c. absorption model results in different parameter estimates, we compared models with only i.v. data or both i.v. and s.c. data. The s.c. absorption models feature an additional compartment for dose administration, characterized by a slow absorption process into the central compartment. In contrast, i.v. doses are administered directly into the central compartment over the course of an hour. Models build on both i.v. and s.c. data were available for 56.5% of mAbs, while 43.5% were estimated on i.v. data only. No difference was observed in <italic toggle="yes">CL</italic>, <italic toggle="yes">V</italic><sub>C</sub>, and <italic toggle="yes">V</italic><sub>P</sub> (<xref rid="f0002" ref-type="fig">Figure 2a</xref>). However, models with absorption processes exhibited 35% lower <italic toggle="yes">Q</italic> (0.41 vs 0.62&#8201;L/d; p&#8201;=&#8201;0.0021) than models with only i.v. administration.
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>(a) Structural popPK parameters of all 160 models were compared across different administration (either i.v. or s.c./i.v.) or elimination routes (either linear or mixed linear and nonlinear elimination). (b) The median estimated structural popPK parameters for each individual mAb were compared based on the origin or subclass of IgG. Statistical significance of the comparisons was determined using Wilcoxon rank tests (* = <italic toggle="yes">p</italic>&lt;0.05, ** = <italic toggle="yes">p</italic>&lt;0.01, *** = <italic toggle="yes">p</italic>&lt;0.005, **** = <italic toggle="yes">p</italic>&lt;0.001).</p></caption><alt-text>Statistical significance was not observed in any comparisons except for those explicitly mentioned in the main text.</alt-text><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0002_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0002_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="3" id="s0003-s2001-s3003"><title>Nonlinear elimination</title><p>Linear clearance is not the sole route of elimination; mixed models incorporate linear and more complex nonlinear mechanisms. Our investigation into various models revealed that 47.5% (<italic toggle="yes">n</italic>&#8201;=&#8201;76) exhibit nonlinear kinetics, encompassing 56.5% (<italic toggle="yes">n</italic>&#8201;=&#8201;39) of mAbs (<xref rid="t0001" ref-type="table">Table 1</xref>). Some models utilized Michaelis&#8211;Menten kinetics (<italic toggle="yes">n</italic>&#8201;=&#8201;32, 42%), while others employed more intricate TMDD models (<italic toggle="yes">n</italic>&#8201;=&#8201;20, 26%), most frequently using a quasi-steady state assumption.<sup><xref rid="cit0014" ref-type="bibr">14</xref></sup> Additionally, a number of models incorporated a time-decaying clearance (<italic toggle="yes">n</italic>&#8201;=&#8201;20, 26%), using only a single parameter to estimate the rate of decay. Other models incorporated time-dependent Michaelis&#8211;Menten elimination (<italic toggle="yes">n</italic>&#8201;=&#8201;5, 6.6%) or linear clearance with an additional time-decaying clearance component (<italic toggle="yes">n</italic>&#8201;=&#8201;5, 6.6%). A full overview is presented in Table S1. Nonlinear elimination is generally attributed to TMDD. In some cases, there can be an association with disease severity and inflammation. For instance, improvement in disease status in oncology reduced the rate of cancer-related cachexia (hypermetabolism), subsequently reducing the clearance of anti-PD-1 and anti-PD-L1 mAbs.<sup><xref rid="cit0015" ref-type="bibr">15&#8211;19</xref></sup></p><p>In the Michaelis&#8211;Menten model, <italic toggle="yes">K</italic><sub>m</sub> indicates the drug concentration at which the elimination rate is half of its maximum (<italic toggle="yes">V</italic><sub>max</sub>). Estimates for both <italic toggle="yes">K</italic><sub>m</sub> and <italic toggle="yes">V</italic><sub>max</sub> vary widely across different targets and target forms (soluble or membrane-bound; Figure S3). For example, daratumumab (anti-CD38) had four models with <italic toggle="yes">V</italic><sub>max</sub> and <italic toggle="yes">K</italic><sub>m</sub> values ranging from 20.2 to 49.9&#8201;mg/d, and 0.05&#8211;0.4&#8201;mg/L, respectively. In contrast, two different anti-EGFR mAbs, necitumumab and panitumumab, had comparable <italic toggle="yes">V</italic><sub>max</sub> values of 13.6 and 12.1&#8201;mg/d, respectively. Due to estimation difficulties, <italic toggle="yes">K</italic><sub>m</sub> was fixed to the lower limit of quantitation in 6 of 31 models.</p><p>It is likely that all mAbs display nonlinear kinetics to some, albeit variable degree, even in models that assume only linear clearance. A certain degree of additional clearance, for example via TMDD, might be incorporated as a slightly larger <italic toggle="yes">CL</italic>, depending in part on the range of observed concentrations present in a data set. Therefore, we compared the linear models to mixed models, the latter incorporating linear and nonlinear elimination. The median value of the linear <italic toggle="yes">CL</italic> component was 26% lower for the mixed models compared to models with linear clearance alone (0.18 vs. 0.25&#8201;L/d; p&#8201;&lt;&#8201;0.0001; <xref rid="f0002" ref-type="fig">Figure 2a</xref>). Furthermore, linear and mixed models showed similar <italic toggle="yes">V</italic><sub>C</sub>, <italic toggle="yes">V</italic><sub>P</sub> and <italic toggle="yes">Q</italic>. These effects remained significant after weight-normalizing the values (Figure S4). The reduced <italic toggle="yes">CL</italic> observed in comparison to linear models remained consistent across different elimination models (Figure S5). Taken together, these results suggest that a certain degree of target-mediated clearance may be captured in <italic toggle="yes">CL</italic> in some models; conversely, by incorporating an additional route of clearance in the model, part of the linear clearance might be accounted for by these additional parameters resulting in a lower estimate of <italic toggle="yes">CL</italic>.</p></sec><sec disp-level="3" id="s0003-s2001-s3004"><title>Impact of mAb characteristics on structural parameter estimates</title><p>Variations in models may also stem from differences in mAb characteristics, including the IgG subclass and the genetic origin. To further explore these differences, we compared models according to these specific mAb characteristics. Chimeric antibodies feature only the variable region from mice, humanized antibodies only the hypervariable regions from mice, and fully human antibodies are derived, e.g., from human variable domain libraries or transgenic mice.<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> Although only a small proportion (11.6%) of therapeutic mAbs are of chimeric origin, they are more prominently represented in the dataset (20%). When comparing antibodies based on their origin (chimeric <italic toggle="yes">n</italic>&#8201;=&#8201;8, humanized <italic toggle="yes">n</italic>&#8201;=&#8201;25, fully human <italic toggle="yes">n</italic>&#8201;=&#8201;36), the median <italic toggle="yes">CL</italic> was found to be around 50% higher in chimeric antibodies (0.33&#8201;L/d) compared to humanized (0.21&#8201;L/d; <italic toggle="yes">p</italic>&#8201;=&#8201;0.036) and fully human antibodies (0.22&#8201;L/d; <italic toggle="yes">p</italic>&#8201;=&#8201;0.028) (<xref rid="f0002" ref-type="fig">Figure 2b</xref>). An approximately two-fold increase in <italic toggle="yes">Q</italic> was observed in chimeric (0.95&#8201;L/d) vs humanized (0.51&#8201;L/d; <italic toggle="yes">p</italic>&#8201;=&#8201;0.0043) or fully human mAbs (0.47&#8201;L/d; <italic toggle="yes">p</italic>&#8201;=&#8201;0.0021). ADA formation is more frequently observed for chimeric antibodies in comparison to humanized/fully human antibodies,<sup><xref rid="cit0021" ref-type="bibr">21</xref></sup> but ADA are not consistently modeled as a covariate. We hypothesize that the increased estimated linear clearance in chimeric antibodies is associated with unaccounted immunogenicity. An alternative explanation would be the lack of TMDD evaluation for chimeric antibodies.</p><p>Immunoglobulin G (IgG) is the most abundant antibody in human serum, and it is divided into four subclasses: IgG1, IgG2, IgG3, and IgG4. Of these, IgG1 and IgG3 are most effective in activating complement and antibody-dependent cellular cytotoxicity, while IgG2 and in particular IgG4&#160;have a less pro-inflammatory phenotype.<sup><xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0023" ref-type="bibr">23</xref></sup> Subclasses of IgG (IgG1 <italic toggle="yes">n</italic>&#8201;=&#8201;47, IgG2 <italic toggle="yes">n</italic>&#8201;=&#8201;6, IgG4 <italic toggle="yes">n</italic>&#8201;=&#8201;15) demonstrated similar PK parameters, except for a 29% increase of <italic toggle="yes">V</italic><sub>P</sub> for IgG1 (2.7&#8201;L) compared to IgG4 (2.1&#8201;L; <italic toggle="yes">p</italic>&#8201;=&#8201;0.0092; <xref rid="f0002" ref-type="fig">Figure 2b</xref>).</p></sec><sec disp-level="3" id="s0003-s2001-s3005"><title>Sample size matters</title><p>Data sets used for different individual model parametrizations varied substantially in size. Therefore, we investigated if there was a relationship between the variation of individual parameter estimates across models and the sample size, the total number of patients used to fit a model. The median (IQR) number of samples used was 5250 (1788; 10223), with a median (IQR) of 8.6 (5.7; 13.3) samples per patient. We examined the correlation between patient sample size and the absolute deviation from the mean parameter estimate. A negative Spearman correlation was observed for all parameters, which was significant for <italic toggle="yes">V</italic><sub>C</sub>, <italic toggle="yes">V</italic><sub>P</sub>, and <italic toggle="yes">Q</italic> (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, Figure S6).</p></sec></sec><sec disp-level="2" id="s0003-s2002"><title>Stochastic model</title><p>An essential component of population PK models is the stochastic model which accounts for variability, originating from various sources and often separated into inter-individual variability (IIV), and residual unexplained variability (RUV). The latter originates from measurement errors, timing inconsistencies in sample collection and model misspecification. In the publications where the RUV model was available, RUV was incorporated either as proportional (<italic toggle="yes">n</italic>&#8201;=&#8201;62) or as a combination of additive and proportional (<italic toggle="yes">n</italic>&#8201;=&#8201;60). During model building, covariates may be identified that explain part of the IIV (see below). The remaining median (IQR) unexplained IIV in the final models was 31.9 CV% (28.2&#8211;38%) and 24 CV% (18&#8211;34.5%), for <italic toggle="yes">CL</italic> and <italic toggle="yes">V</italic><sub>C</sub>, respectively (<xref rid="f0003" ref-type="fig">Figure 3a</xref>). To assess the extent of IIV explained by covariates, we assessed 19 models for which information was available for both the base models (without covariates) and the final models. On average, the IIV in <italic toggle="yes">CL</italic> and <italic toggle="yes">V</italic><sub>C</sub> dropped from 43% to 35.7% (<italic toggle="yes">n</italic>&#8201;=&#8201;19) and from 28.8% to 24.4% (<italic toggle="yes">n</italic>&#8201;=&#8201;17), respectively (<xref rid="f0003" ref-type="fig">Figure 3b</xref>). These results indicate that covariates explain only 15&#8211;17% of the total IIV. Importantly, when we compare the median variability between individuals in base models (<xref rid="f0003" ref-type="fig">Figure 3</xref>) with the variability in estimates across models (<xref rid="f0001" ref-type="fig">Figure 1</xref>), we observe similar values for <italic toggle="yes">V</italic><sub>C</sub> (28.8% vs. 25.0%) and <italic toggle="yes">CL</italic> (43% vs. 54.6%), respectively.
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><p>Inter-individual variability (IIV) reported across models (a) distribution of IIV in %CV on parameters across final models (including covariates). (b) Distributions of IIV before (base model) and after (final model) adding covariates in publications where both models were reported.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0003_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0003_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="2" id="s0003-s2003"><title>Covariate model</title><p>In order to provide deeper insight into the determinants of mAbs PK parameters, we analyzed and summarized the most often reported covariates (<xref rid="t0002" ref-type="table">Table 2</xref>), updating previous work accordingly.<sup><xref rid="cit0008" ref-type="bibr">8</xref></sup>
<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Commonly included covariates in the 160 published models of this analysis.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Covariate</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">CL</italic></th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub>C</sub></th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub>P</sub></th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">Q</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Body size descriptors</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Body weight</td><td align="center" colspan="1" rowspan="1">66.9% (107)</td><td align="center" colspan="1" rowspan="1">71.2% (114)</td><td align="center" colspan="1" rowspan="1">30.6% (49)</td><td align="center" colspan="1" rowspan="1">21.2% (34)</td></tr><tr><td align="left" colspan="1" rowspan="1">Body surface area</td><td align="center" colspan="1" rowspan="1">3.8% (6)</td><td align="center" colspan="1" rowspan="1">6.9% (11)</td><td align="center" colspan="1" rowspan="1">1.9% (3)</td><td align="center" colspan="1" rowspan="1">0.6% (1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lean body weight</td><td align="center" colspan="1" rowspan="1">1.2% (2)</td><td align="center" colspan="1" rowspan="1">1.2% (2)</td><td align="center" colspan="1" rowspan="1">0.6% (1)</td><td align="center" colspan="1" rowspan="1">0.6% (1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Body mass index</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">1.2% (2)</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Fat-free mass</td><td align="center" colspan="1" rowspan="1">1.2% (2)</td><td align="center" colspan="1" rowspan="1">1.2% (2)</td><td align="center" colspan="1" rowspan="1">1.2% (2)</td><td align="center" colspan="1" rowspan="1">0.6% (1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="center" colspan="1" rowspan="1">28.1% (45)</td><td align="center" colspan="1" rowspan="1">31.2% (50)</td><td align="center" colspan="1" rowspan="1">2.5% (4)</td><td align="center" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Albumin</td><td align="center" colspan="1" rowspan="1">41.9% (67)</td><td align="center" colspan="1" rowspan="1">10.6% (17)</td><td align="center" colspan="1" rowspan="1">1.2% (2)</td><td align="center" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">ADA</td><td align="center" colspan="1" rowspan="1">16.2% (26)</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">&#8211;</td></tr></tbody></table></table-wrap></p><p>Body weight was the most used body size descriptor, while 25 of 160 did not include any allometric scaling. Instead of estimating the allometric scaling exponent, 19 models fixed at least one of the four base parameters to the standard size exponent (0.75 for <italic toggle="yes">CL</italic> and <italic toggle="yes">Q</italic>; 1 for <italic toggle="yes">V</italic><sub>C</sub> and <italic toggle="yes">V</italic><sub>P</sub>).<sup><xref rid="cit0024" ref-type="bibr">24</xref>,<xref rid="cit0025" ref-type="bibr">25</xref></sup> The median (IQR) reference weight was 70 (69; 75), with 30 models using 70&#8201;kg as the reference weight. The median (IQR) allometric exponent for body weight on <italic toggle="yes">CL</italic> and <italic toggle="yes">V</italic><sub>C</sub>, when estimated, was 0.62 (0.52; 0.81) and 0.56 (0.47; 0.76), respectively (<xref rid="f0004" ref-type="fig">Figure 4a</xref>). Sex was found to be a significant covariate in 37.5% of models. <italic toggle="yes">CL</italic> was increased by a median (IQR) of 19% (15%; 26%) in male compared to female (<xref rid="f0004" ref-type="fig">Figure 4b</xref>). The effects of body weight and sex on parameters are interdependent and not entirely separate variables. Including a size descriptor as covariate reduced the effect size of sex on clearance from 1.3 to 1.18 (<xref rid="f0004" ref-type="fig">Figure 4e</xref>), while including sex altered the exponent of weight on clearance from 0.75 to 0.53 and weight on central volume from 0.70 to 0.48 (<xref rid="f0004" ref-type="fig">Figure 4f,g</xref>).
<fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4.</label><caption><p>Estimates of covariate effects on parameters. (a) Body weight exponent. (b) Male coefficient versus female. (c) Albumin exponent. (d) ADA positive coefficient versus negative. (e) Sex coefficient on clearance, with or without accounting for size descriptors in the model. (f) Exponent of weight on clearance, with or without inclusion of sex as covariate. (g) Exponent of weight on central volume, with or without inclusion of sex as covariate. (h) Terminal half-life versus weight in two commonly used weight-based covariate models, either having weight as a covariate only on CL and V<sub>C</sub> (blue dashed line) or on CL, V<sub>C</sub>, V<sub>P</sub>, Q (black solid line).</p></caption><alt-text>(a) Estimates of body weight exponents on parameters ranging from 0.15 to 1.75, with most values falling between 0.5 and 0.75. (b) The majority of coefficient estimates for male versus female fall within the range of 1.1 to 1.25. (h) The half-life ranges from 24 d at 40 kg to 18 d at 100 kg. For weight on clearance, intercompartmental clearance, and central and peripheral volume, the half-life ranges from 19 d at 40 kg to 21 d at 100 kg.</alt-text><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0004_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0004_PB.jpg"/></alternatives></fig></p><p>Serum albumin levels were negatively associated with <italic toggle="yes">CL</italic> in 41.9% of models, and in 17 models, it was also included on <italic toggle="yes">V</italic><sub>C</sub>. The median (IQR) reference serum albumin level was 40 (39; 42.8) g/L. The median (IQR) power coefficient for albumin on <italic toggle="yes">CL</italic> was &#8722;0.90 (&#8722;1.1; &#8722;0.69; <xref rid="f0004" ref-type="fig">Figure 4c</xref>).</p><p>Immunogenicity is more common with chimeric antibodies, though it can also occur with humanized ones, but not all mAbs trigger a measurable immune response. Of 160 models, only 26 representing 13 different mAbs reported a significant association of ADAs on clearance. Of these 13 mAbs, only infliximab was chimeric while the others were either humanized or fully human. In all these models, ADAs were included as a covariate with a coefficient on clearance for patients who tested positive. When averaged per mAb, the median (IQR) coefficient on clearance was 1.39 (1.19&#8211;1.49) if the patient was ADA positive (<xref rid="f0004" ref-type="fig">Figure 4d</xref>). However, one model considered a continuous function between ADA titer and its effect.<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup> Despite estimating a 14% effect, it was considered irrelevant as it was below the 20% threshold. In 42 models, ADAs were not found to be significant. Additionally, 22 models did not evaluate ADAs as a covariate because few to no patients developed ADA responses or the response was transient.</p><p>The three most frequently identified combinations of covariates were: 1) 20 models incorporating weight only on <italic toggle="yes">CL</italic> and <italic toggle="yes">V</italic><sub>C</sub>, 2) 15 models with weight on <italic toggle="yes">CL</italic>, <italic toggle="yes">V</italic><sub>C</sub>, <italic toggle="yes">V</italic><sub>P</sub>, <italic toggle="yes">Q</italic>, and 3) 19 models with weight and sex only on <italic toggle="yes">CL</italic> and <italic toggle="yes">V</italic><sub><italic toggle="yes">C</italic></sub>. Interestingly, the trend in terminal half-life versus weight was opposite between combinations 1 and 2 (<xref rid="f0004" ref-type="fig">Figure 4H</xref>). Specifically, for an individual weighing 40&#8201;kg, the terminal half-life was 28% longer with combination I compared to combination II (24.4 vs 19&#8201;d). However, after a single 100&#8201;mg dose, total drug exposure in a 40&#8201;kg individual was only 10% higher with combination 2 compared to combination I (Figure S7). This difference in exposure was eliminated after multiple doses, resulting in equivalent exposure levels for both combinations. Exposure decreases with increasing body weight; therefore, weight-based dosing is commonly used in the clinic to achieve consistent exposure across varying body weights.</p></sec><sec disp-level="2" id="s0003-s2004"><title>Generic model</title><p>Based on our results, we hypothesized that the median parameter values derived from our systematic meta-analysis could be used as generic a priori or fixed estimates of parameters. Indeed, for infliximab and rituximab, two efficacious and widely used mAbs for which multiple models have been independently developed, model estimates are found to cluster around the median parameter values from this analysis (<xref rid="f0005" ref-type="fig">Figure 5a,b</xref>). To further illustrate this point, we performed a simulation of a &#8216;generic population PK model&#8217; capturing the IgG homeostasis in the absence of TDMM. A two-compartment model with/without subcutaneous absorption and linear clearance was based on the median parameter estimates (<xref rid="f0001" ref-type="fig">Figure 1c</xref>). We simulated PK after a single-dose administration given this generic model. This generic model results in very plausible kinetics, representing the overall trend of the individual core models (<xref rid="f0005" ref-type="fig">Figure 5c,d</xref>). Simulations were performed in 500 virtual individuals using population parameter values, with random effects sampled from the median inter-individual variability (<xref rid="f0003" ref-type="fig">Figure 3</xref>), highlighting the extensive variability between subjects. Given this variability, the terminal half-life determined from the simulation was 21.3&#8201;d, with the 5th and 95th percentiles having terminal half-lives of 13.4 and 35.5&#8201;d, respectively. We suggest that this overview may aid in choosing a priori parameter estimates when developing new mAb PK models. Additionally, allometric scaling may be applied given the median estimates of power coefficients that we found. Furthermore, this model could be extended a priori with covariates known to influence IgG homeostasis, and a model for TDMM if appropriate.
<fig position="float" id="f0005" fig-type="figure" orientation="portrait"><label>Figure 5.</label><caption><p>The average of models in this meta-analysis versus observed values. Estimates of infliximab and rituximab models for (a) clearance (CL) and central volume (V<sub>C</sub>) and (b) intercompartmental clearance (Q) and peripheral volume (V<sub>P</sub>). Solid black line represents the median parameter estimate of all 144 models. (c) Demonstration of a generic model compared to all models in our analysis. Simulated concentration-time profiles in the central compartment following a 100 mg i.v. dose were generated either for 1) all models using reported population parameters without target-mediated elimination, or 2) the generic model using median parameter estimates with 500 virtual individuals sampling from the inter-individual variability (IIV). Solid lines representing the median and dotted lines demonstrating the 5<sup>th</sup> and 95<sup>th</sup> percentiles of the generic model. Black translucent lines show all i.v. models (<italic toggle="yes">n</italic>=100) using the typical population parameter estimates. Model specifications: CL = 0.22 L/d, V<sub>C</sub> = 3.42 L, V<sub>P</sub> = 2.68 L, Q = 0.54 L/d, ka = 0.25/d, F = 0.69, IIV<sub>CL</sub> = 31.9% (&#969;<sup>2</sup> = 0.097), IIV<sub>VC</sub> = 24% (&#969;<sup>2</sup> = 0.056), IIV<sub>ka</sub> = 54.8% (&#969;<sup>2</sup> = 0.26). (D) Simulation of s.c. models (<italic toggle="yes">n</italic>=44).</p></caption><alt-text>(a, b) Estimates for pharmacokinetic parameters include clearance values ranging from 0.12 to 1.2 l/d, central volume values from 0.95 to 5 l, peripheral volume values from 1.2 to 12 l, and intercompartmental clearance values from 0.06 to 4.8 l/d. (c, d) The concentration&#8211;time profiles representing the 5th and 95th percentiles of the 500 simulated individuals in the generic model successfully capture 90% of the profiles from all published models following both i.v. and s.c. administration.</alt-text><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0005_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2512217_F0005_PB.jpg"/></alternatives></fig></p></sec></sec><sec disp-level="1" id="s0004"><title>Discussion</title><p>All models are inherently flawed and represent only a fit to the available data. Through extensive modeling efforts and estimating separate models for each mAb, our meta-analysis captures the general trends and the impact of model configurations on parameters across these models.<sup><xref rid="cit0015" ref-type="bibr">15&#8211;19</xref>,<xref rid="cit0026" ref-type="bibr">26&#8211;175</xref></sup> Structural parameter estimates fell within a narrow range across most mAbs, especially for <italic toggle="yes">V</italic><sub>C</sub>, <italic toggle="yes">CL</italic>, and <italic toggle="yes">k</italic><sub>a</sub>. A significantly lower linear <italic toggle="yes">CL</italic> was observed for models that included nonlinear elimination. We also found a markedly lower <italic toggle="yes">CL</italic> for fully human and humanized mAbs compared to chimeric mAbs. The most commonly used covariate, weight, exhibited a coefficient that differed from standard allometric scaling, and sex and weight were found to be partly compensating covariates. Most importantly, this work suggests that variability in structural parameter estimates across mAbs is to a substantial degree accidental in nature rather than linked to specific properties of specific mAbs. IIV remains largely unexplained even after incorporating covariates. Our analysis demonstrates that variability in estimates originates from various sources, and that median values for parameters of the distribution volumes, linear clearance, and absorption derived from published models appear to provide very plausible generic a priori estimates.</p><p>Similarities in structure, size, and degradation of mAbs suggest that their linear clearance is comparable between mAbs. Radiolabeled endogenous IgG in the intravascular pool is reported to be catabolized at a rate of 6.3% per day, which, taken the central volume of 3.42&#8201;L in this work, would equate to a value of 0.215&#8201;L/d.<sup><xref rid="cit0176" ref-type="bibr">176</xref></sup> A previous approach estimated <italic toggle="yes">CL</italic> at 0.21&#8201;L/d, very similar to the average of 0.22&#8201;L/d here.<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup> Of note, the PK of mAbs does depend on the total IgG concentration due to competition for the FcRn, but few models use total IgG concentrations as covariate.<sup><xref rid="cit0177" ref-type="bibr">177</xref></sup> No substantial differences were observed between IgG1, IgG2, and IgG4 subclasses, in line with previous literature on IgG1 and IgG4 clearance.<sup><xref rid="cit0177" ref-type="bibr">177</xref></sup></p><p>The linear clearance is related to the crucial interaction between FcRn and mAb, which extends the half-life of IgG via endosomal capture and re-release into the circulation. This interaction can be assessed using various techniques, including binding assays, column retention assays, or <italic toggle="yes">in vitro</italic> transcytosis assays, in order to predict antibody half-life or clearance rate.<sup><xref rid="cit0178" ref-type="bibr">178&#8211;180</xref></sup> However, these assays have not consistently proven effective in accurately predicting the <italic toggle="yes">CL</italic> of conventional mAbs. Specific mAbs could behave differently, e.g., due to unusual surface charge on Fab domains.<sup><xref rid="cit0181" ref-type="bibr">181&#8211;183</xref></sup> Our analysis indicates that most mAbs are cleared in a very similar manner, and the differences in their elimination via the FcRn pathway may be relatively small in most cases. Nevertheless, specific features such as Fab glycans might affect FcRn recycling, and certain Fc fusion proteins, including etanercept, have a much lower half-life compared to most mAbs.<sup><xref rid="cit0184" ref-type="bibr">184&#8211;186</xref></sup></p><p>Several other routes of clearance may contribute to the overall clearance and affect the estimate of <italic toggle="yes">CL</italic>. TMDD may become difficult to detect in the concentration range where linear clearance predominates. We found a 26% lower median clearance in models that included nonlinear kinetics, compared to linear models (0.18 vs. 0.25&#8201;L/d), probably indicating that a low rate of target-mediated clearance is captured in <italic toggle="yes">CL</italic> in the latter case. Although a previous analysis did not report significant differences in <italic toggle="yes">CL</italic> in nonlinear versus linear models, not only were fewer models included than in the current work, it also included traditional PK models instead of population models.<sup><xref rid="cit0187" ref-type="bibr">187</xref></sup> Immunogenicity was only included in a subset of models. Sometimes only a few subjects develop ADAs, and responses can be weak and/or transient and are therefore not relevant. Nevertheless, our analysis revealed that chimeric mAbs demonstrated a higher estimated <italic toggle="yes">CL</italic>, indicating unaccounted immunogenicity, since ADA formation is more implicated with chimeric mAbs compared to human(ized) ones. Challenges in detecting ADA antibodies might explain their apparent absence.<sup><xref rid="cit0188" ref-type="bibr">188</xref></sup></p><p>The IIV in the different parameters, including <italic toggle="yes">V</italic><sub>P</sub> and <italic toggle="yes">Q</italic>, approximates the variability in model estimates of structural PK parameters. Although part of the variation in <italic toggle="yes">Q</italic> might be attributed to increased lymphatic flow in conditions like rheumatoid arthritis and cancers, most variation is likely due to estimation difficulties of these parameters posed by the lack of direct measurements from the peripheral volume.<sup><xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0189" ref-type="bibr">189</xref></sup> It can be advantageous to fix parameters like <italic toggle="yes">V</italic><sub>P</sub> and <italic toggle="yes">Q</italic> to alleviate identifiability or parameter estimation issues, and the median values reported here might serve as reasonable a priori parameter estimates.</p><p>Size descriptors are frequently found as the most relevant covariate. It is not surprising that confounding effects of body weight and sex were identified. Our data indicated that descriptors are applied in various combinations to parameters, leading to different effects on half-life. Often, the data available is insufficient to accurately map these relationships, necessitating the use of standard a priori estimates. However, standard allometric scaling is highly debated due to the lack of an universal allometric exponent and its questionable biological basis.<sup><xref rid="cit0190" ref-type="bibr">190</xref></sup> In the context of mAbs, differences in clearance between males and females may be attributed to the proportion of fat, due to its limited impact on metabolic rate and distribution volume of mAbs.<sup><xref rid="cit0191" ref-type="bibr">191&#8211;193</xref></sup> Hence, body weight is likely not the optimal predictor; fat-free mass or lean body mass could be used instead, although it was only utilized in two models in this study.<sup><xref rid="cit0055" ref-type="bibr">55</xref>,<xref rid="cit0175" ref-type="bibr">175</xref></sup> Overall, applying the allometric scaling exponents from the largest set of population PK models to date could be advantageous.</p><p>In comparing our general model to the population PK models for infliximab and rituximab, we observe that average trends are consistent across different indications. Infliximab, primarily used in gastroenterology and rheumatology, and rituximab, administered in oncology, rheumatology, and nephrology, both show significant variability in estimates even within the same patient population. Consequently, this suggests that IgG homeostasis is largely consistent across populations, with any variations likely accounted for by covariates such as albumin, while the rest may be related to TMDD. All in all, we hypothesize that a generic population PK model might reflect the PK of IgG homeostasis for many mAbs and enhance the accuracy of parameter estimation and parameter identifiability when used as starting point for model development. For example, a generic model could help identify mAb-specific abnormalities in its PK. One such attempt involved developing a model based on combined data from reported models to estimate clearance and bioavailability using only s.c. data, which normally requires i.v. data.<sup><xref rid="cit0187" ref-type="bibr">187</xref></sup> In the context of personalized dosing, averaging several models of infliximab boosted performance for model-guided dosing.<sup><xref rid="cit0194" ref-type="bibr">194</xref></sup> Given the potential of pharmacometrics in optimizing treatment strategies, implementing generic models may further aid in these processes, especially in providing generic parameter estimates that may be superior to specific estimates derived from a single data set.</p></sec><sec disp-level="1" id="s0005"><title>Conclusion</title><p>This meta-analysis highlights the similarities in PK models, across various mAb modalities, and the challenges posed by sparse data. We suggest that this overview may aid in choosing a priori parameter estimates when developing new mAb PK models. A generic model may furthermore provide a framework to place mAb-specific PK characteristics in a general context. Furthermore, we propose that a standardized PK model can facilitate early model-informed drug development, model building and pharmacodynamic modeling.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM8525" position="float" content-type="local-data" orientation="portrait"><caption><title>SupplementAltClean.docx</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="KMAB_A_2512217_SM8525.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM8524" position="float" content-type="local-data" orientation="portrait"><caption><title>Suppl_TableS1.xlsx</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="KMAB_A_2512217_SM8524.xlsx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec sec-type="COI-statement" disp-level="1" id="s0006"><title>Disclosure statement</title><p>T.R. received research grants from Genmab; consulting fees from Novartis (all payments to institution). This funding did not influence the design, execution, interpretation, or reporting of this study. The authors declare no other competing interests.</p></sec><sec sec-type="supplementary-material" disp-level="1" id="s0007"><title>Supplementary material</title><p>Supplemental data for this article can be accessed online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1080/19420862.2025.2512217" ext-link-type="uri">https://doi.org/10.1080/19420862.2025.2512217</ext-link></p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lyu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Hui</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shentu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dalby</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>The global landscape of approved antibody therapies</article-title>. <source>Antib Ther</source>. <year>2022</year>;<volume>5</volume>(<issue>4</issue>):<fpage>233</fpage>&#8211;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1093/abt/tbac021</pub-id>.<pub-id pub-id-type="pmid">36213257</pub-id><pub-id pub-id-type="pmcid">PMC9535261</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cain</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Anguiano</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Shih</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Chai</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></string-name></person-group><article-title>Impact of IgG subclass on molecular properties of monoclonal antibodies</article-title>. <source>Mabs-austin</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>1993768</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2021.1993768</pub-id>.<pub-id pub-id-type="pmcid">PMC8726687</pub-id><pub-id pub-id-type="pmid">34763607</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="webpage"><article-title>IMGT/mAb-DB, the international database of therapeutic monoclonal antibodies</article-title>. [<date-in-citation>Accessed 2024 <month>Nov</month><day>28</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.imgt.org/mAb-DB" ext-link-type="uri">https://www.imgt.org/mAb-DB</ext-link>.</mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="newspaper"><person-group person-group-type="author"><string-name name-style="western"><surname>Poiron</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ginestoux</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ehrenmann, Duroux</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lefranc</surname><given-names>M-P.</given-names></string-name></person-group><article-title>IMGT/mAb-DB: the IMGT&#174; database for therapeutic monoclonal antibodies</article-title>. <year>2010</year>.</mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dostalek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gardner</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gurbaxani</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Chetty</surname><given-names>MP</given-names></string-name></person-group>. <article-title>Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies</article-title>. <source>Clin Pharmacokinet</source>. <year>2013</year>;<volume>52</volume>(<issue>2</issue>):<fpage>83</fpage>&#8211;<lpage>124</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-012-0027-4</pub-id>.<pub-id pub-id-type="pmid">23299465</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dirks</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Meibohm</surname><given-names>B</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of therapeutic monoclonal antibodies: Clin</article-title>. <source>Pharmacokinet</source>. <year>2010</year>;<volume>49</volume>(<issue>10</issue>):<fpage>633</fpage>&#8211;<lpage>659</lpage>. doi: <pub-id pub-id-type="doi">10.2165/11535960-000000000-00000</pub-id>.<pub-id pub-id-type="pmid">20818831</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gill</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Machavaram</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Chetty</surname><given-names>M</given-names></string-name></person-group>. <article-title>Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics</article-title>. <source>Clin Pharmacokinet</source>. <year>2016</year>;<volume>55</volume>(<issue>7</issue>):<fpage>789</fpage>&#8211;<lpage>805</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-015-0361-4</pub-id>.<pub-id pub-id-type="pmid">26818483</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bensalem</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ternant</surname><given-names>D</given-names></string-name></person-group>. <article-title>Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications</article-title>. <source>Clin Pharmacokinet</source>. <year>2020</year>;<volume>59</volume>(<issue>7</issue>):<fpage>857</fpage>&#8211;<lpage>874</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-020-00874-2</pub-id>.<pub-id pub-id-type="pmid">32170579</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bajaj</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Suryawanshi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>M</given-names></string-name></person-group>. <article-title>Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology</article-title>. <source>Br J Clin Pharmacol</source>. <year>2019</year>;<volume>85</volume>(<issue>9</issue>):<fpage>2045</fpage>&#8211;<lpage>2058</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.13996</pub-id>.<pub-id pub-id-type="pmid">31140642</pub-id><pub-id pub-id-type="pmcid">PMC6710515</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Minichmayr</surname><given-names>IK</given-names></string-name>, <string-name name-style="western"><surname>Dreesen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Centanni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hoffert</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Wicha</surname><given-names>SG</given-names></string-name></person-group>. <article-title>Model-informed precision dosing: state of the art and future perspectives</article-title>. <source>Adv Drug Delivery Rev</source>. <year>2024</year>;<volume>215</volume>:<fpage>115421</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.addr.2024.115421</pub-id>.<pub-id pub-id-type="pmid">39159868</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McEneny-King</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chelle</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Foster</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Keepanasseril</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Iorio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Edginton</surname><given-names>AN</given-names></string-name></person-group>. <article-title>Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2019</year>;<volume>46</volume>(<issue>5</issue>):<fpage>411</fpage>&#8211;<lpage>426</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10928-019-09634-7</pub-id>.<pub-id pub-id-type="pmid">31104228</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>National Center for Biotechnology Information (NCBI)</collab></person-group>. <publisher-loc>Bethesda (MD)</publisher-loc>: <publisher-name>National Library of Medicine (US</publisher-name>. [<date-in-citation>Accessed 2024 <month>Nov</month><day>28</day></date-in-citation>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/</ext-link>.</mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mizuta</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tsubotani</surname><given-names>A</given-names></string-name></person-group>. <article-title>Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters</article-title>. <source>Chem Pharm Bull (Tokyo)</source>. <year>1985</year>;<volume>33</volume>(<issue>4</issue>):<fpage>1620</fpage>&#8211;<lpage>1632</lpage>. doi: <pub-id pub-id-type="doi">10.1248/cpb.33.1620</pub-id>.<pub-id pub-id-type="pmid">4042238</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koch</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Schropp</surname><given-names>J</given-names></string-name></person-group>. <article-title>Target-mediated drug disposition with drug&#8211;drug interaction, part I: single drug case in alternative formulations</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2017</year>;<volume>44</volume>(<issue>1</issue>):<fpage>17</fpage>&#8211;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10928-016-9501-1</pub-id>.<pub-id pub-id-type="pmid">28074395</pub-id><pub-id pub-id-type="pmcid">PMC5478890</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bajaj</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors: model-based population pharmacokinetic analysis of nivolumab</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2017</year>;<volume>6</volume>(<issue>1</issue>):<fpage>58</fpage>&#8211;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12143</pub-id>.<pub-id pub-id-type="pmcid">PMC5270302</pub-id><pub-id pub-id-type="pmid">28019091</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sanghavi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Statkevich</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vezina</surname><given-names>HE</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>29</fpage>&#8211;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12477</pub-id>.<pub-id pub-id-type="pmcid">PMC6966186</pub-id><pub-id pub-id-type="pmid">31709718</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baverel</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Dubois</surname><given-names>VFS</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mukhopadhyay</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dennis</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Ben</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status</article-title>. <source>Clin Pharmacol Ther</source>. <year>2018</year>;<volume>103</volume>(<issue>4</issue>):<fpage>631</fpage>&#8211;<lpage>642</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.982</pub-id>.<pub-id pub-id-type="pmid">29243223</pub-id><pub-id pub-id-type="pmcid">PMC5887840</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bender</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C-C</given-names></string-name>, <string-name name-style="western"><surname>Marchand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Vadhavkar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B&#8208;cell non&#8208;Hodgkin lymphoma</article-title>. <source>Clin Transl Sci</source>. <year>2024</year>;<volume>17</volume>(<issue>6</issue>):<fpage>e13825</fpage>. doi: <pub-id pub-id-type="doi">10.1111/cts.13825</pub-id>.<pub-id pub-id-type="pmid">38808543</pub-id><pub-id pub-id-type="pmcid">PMC11134317</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>SXW</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Iwaki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kobos</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Stephenson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kemmerer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Uhlar</surname><given-names>CM</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response with teclistamab in patients with relapsed/Refractory multiple myeloma: results from MajesTEC-1</article-title>. <source>Targeted Oncology</source>. <year>2023</year>;<volume>18</volume>(<issue>5</issue>):<fpage>667</fpage>&#8211;<lpage>684</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11523-023-00989-z</pub-id>.<pub-id pub-id-type="pmid">37713090</pub-id><pub-id pub-id-type="pmcid">PMC10518021</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weiner</surname><given-names>LM</given-names></string-name></person-group>. <article-title>Fully human therapeutic monoclonal antibodies</article-title>. <source>J Immunother (1991)</source>. <year>2006</year>;<volume>29</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.cji.0000192105.24583.83</pub-id>.<pub-id pub-id-type="pmid">16365595</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname><given-names>WYK</given-names></string-name>, <string-name name-style="western"><surname>Foote</surname><given-names>J</given-names></string-name></person-group>. <article-title>Immunogenicity of engineered antibodies</article-title>. <source>Methods</source>. <year>2005</year>;<volume>36</volume>(<issue>1</issue>):<fpage>3</fpage>&#8211;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ymeth.2005.01.001</pub-id>.<pub-id pub-id-type="pmid">15848070</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schroeder</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Cavacini</surname><given-names>L</given-names></string-name></person-group>. <article-title>Structure and function of immunoglobulins</article-title>. <source>J Allergy Clin Immun</source>. <year>2010</year>;<volume>125</volume>(<issue>2</issue>):<fpage>S41</fpage>&#8211;<lpage>S52</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.046</pub-id>.<pub-id pub-id-type="pmid">20176268</pub-id><pub-id pub-id-type="pmcid">PMC3670108</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vidarsson</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dekkers</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rispens</surname><given-names>T</given-names></string-name></person-group>. <article-title>IgG subclasses and Allotypes: from structure to effector functions</article-title>. <source>Front Immunol</source>. <year>2014</year>;<volume>5</volume>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2014.00520</pub-id>.<pub-id pub-id-type="pmcid">PMC4202688</pub-id><pub-id pub-id-type="pmid">25368619</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Holford</surname><given-names>NHG</given-names></string-name></person-group>. <article-title>A size standard for pharmacokinetics: Clin</article-title>. <source>Clin Pharmacokinet</source>. <year>1996</year>;<volume>30</volume>(<issue>5</issue>):<fpage>329</fpage>&#8211;<lpage>332</lpage>. doi: <pub-id pub-id-type="doi">10.2165/00003088-199630050-00001</pub-id>.<pub-id pub-id-type="pmid">8743333</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Holford</surname><given-names>NHG</given-names></string-name></person-group>. <article-title>Mechanism-based concepts of size and maturity in pharmacokinetics</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>2008</year>;<volume>48</volume>(<issue>1</issue>):<fpage>303</fpage>&#8211;<lpage>332</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev.pharmtox.48.113006.094708</pub-id>.<pub-id pub-id-type="pmid">17914927</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Panoilia</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Schindler</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Samantas</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Aravantinos</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kalofonos</surname><given-names>HP</given-names></string-name>, <string-name name-style="western"><surname>Christodoulou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Patrinos</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Sivolapenko</surname><given-names>G</given-names></string-name></person-group>. <article-title>A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2015</year>;<volume>75</volume>(<issue>4</issue>):<fpage>791</fpage>&#8211;<lpage>803</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-015-2701-3</pub-id>.<pub-id pub-id-type="pmid">25687989</pub-id><pub-id pub-id-type="pmcid">PMC4365273</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Netterberg</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C-C</given-names></string-name>, <string-name name-style="western"><surname>Molinero</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Budha</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sukumaran</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stroh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></string-name></person-group>. <article-title>A PK/PD analysis of circulating biomarkers and their relationship to tumor response in atezolizumab&#8208;treated non&#8208;small cell lung cancer patients</article-title>. <source>Clin Pharmacol Ther</source>. <year>2019</year>;<volume>105</volume>(<issue>2</issue>):<fpage>486</fpage>&#8211;<lpage>495</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.1198</pub-id>.<pub-id pub-id-type="pmid">30058723</pub-id><pub-id pub-id-type="pmcid">PMC6704358</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hurkmans</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Basak</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>van Dijk</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mercieca</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Schreurs</surname><given-names>MWJ</given-names></string-name>, <string-name name-style="western"><surname>Wijkhuijs</surname><given-names>AJM</given-names></string-name>, <string-name name-style="western"><surname>Bins</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hoop</surname><given-names>EOD</given-names></string-name>, <string-name name-style="western"><surname>Debets</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Joerger</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients</article-title>. <source>J For Immunother Cancer</source>. <year>2019</year>;<volume>7</volume>(<issue>1</issue>):<fpage>192</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40425-019-0669-y</pub-id>.<pub-id pub-id-type="pmcid">PMC6642527</pub-id><pub-id pub-id-type="pmid">31324223</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salinger</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Endres</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Gibbs</surname><given-names>MA</given-names></string-name></person-group>. <article-title>A semi&#8208;mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first&#8208;in&#8208;human single ascending dose study</article-title>. <source>Clin Pharmacol Drug Dev</source>. <year>2014</year>;<volume>3</volume>(<issue>4</issue>):<fpage>276</fpage>&#8211;<lpage>283</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpdd.103</pub-id>.<pub-id pub-id-type="pmid">27128833</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lioger</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Edupuganti</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Mulleman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Passot</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Desvignes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bejan&#8208;Angoulvant</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Thibault</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gouilleux&#8208;Gruart</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>M&#233;let</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Paintaud</surname><given-names>G</given-names></string-name>, et al</person-group>. <article-title>Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients</article-title>. <source>Br J Clin Pharmacol</source>. <year>2017</year>;<volume>83</volume>(<issue>8</issue>):<fpage>1773</fpage>&#8211;<lpage>1781</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.13270</pub-id>.<pub-id pub-id-type="pmid">28230269</pub-id><pub-id pub-id-type="pmcid">PMC5510084</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Caulet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lecomte</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bouch&#233;</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Rollin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gouilleux-Gruart</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Azzopardi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>L&#233;ger</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Borg</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Douillard</surname><given-names>J-Y</given-names></string-name>, <string-name name-style="western"><surname>Manfredi</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients</article-title>. <source>Clin Pharmacokinet</source>. <year>2016</year>;<volume>55</volume>(<issue>11</issue>):<fpage>1381</fpage>&#8211;<lpage>1394</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-016-0406-3</pub-id>.<pub-id pub-id-type="pmid">27312193</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ait&#8208;Oudhia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mager</surname><given-names>D</given-names></string-name></person-group>. <article-title>Bridging clinical outcomes of canakinumab treatment in patients with rheumatoid arthritis with a population model of IL&#8208;1&#946; kinetics</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2012</year>;<volume>1</volume>(<issue>9</issue>):<fpage>1</fpage>&#8211;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1038/psp.2012.6</pub-id>.<pub-id pub-id-type="pmcid">PMC3603473</pub-id><pub-id pub-id-type="pmid">23835885</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Le Louedec</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Alix&#8208;Panabi&#232;res</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lafont</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Allal</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Garrel</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Digue</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Guigay</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cupissol</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Delord</surname><given-names>J-P</given-names></string-name>, <string-name name-style="western"><surname>Lallemant</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients</article-title>. <source>Br J Clin Pharmacol</source>. <year>2019</year>;<volume>85</volume>(<issue>6</issue>):<fpage>1357</fpage>&#8211;<lpage>1366</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.13907</pub-id>.<pub-id pub-id-type="pmid">30811063</pub-id><pub-id pub-id-type="pmcid">PMC6533440</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pointreau</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Azzopardi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ternant</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Calais</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Paintaud</surname><given-names>G</given-names></string-name></person-group>. <article-title>Cetuximab pharmacokinetics influences overall survival in patients with head and neck cancer</article-title>. <source>Ther Drug Monit</source>. <year>2016</year>;<volume>38</volume>(<issue>5</issue>):<fpage>567</fpage>&#8211;<lpage>572</lpage>. doi: <pub-id pub-id-type="doi">10.1097/FTD.0000000000000321</pub-id>.<pub-id pub-id-type="pmid">27631463</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Azzopardi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lecomte</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ternant</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Boisdron-Celle</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Piller</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Morel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gouilleux-Gruart</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vignault-Desvignes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Watier</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gamelin</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients</article-title>. <source>Clin Cancer Res</source>. <year>2011</year>;<volume>17</volume>(<issue>19</issue>):<fpage>6329</fpage>&#8211;<lpage>6337</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1081</pub-id>.<pub-id pub-id-type="pmid">21953502</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Visich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Allison</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2013</year>;<volume>71</volume>(<issue>3</issue>):<fpage>575</fpage>&#8211;<lpage>580</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-012-2031-7</pub-id>.<pub-id pub-id-type="pmid">23228985</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pouliquen</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Kornmann</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Barton</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Ortega</surname><given-names>HG</given-names></string-name></person-group>. <article-title>Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>2015</year>;<volume>53</volume>(<issue>12</issue>):<fpage>1015</fpage>&#8211;<lpage>1027</lpage>. doi: <pub-id pub-id-type="doi">10.5414/CP202446</pub-id>.<pub-id pub-id-type="pmid">26445140</pub-id><pub-id pub-id-type="pmcid">PMC4647865</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stroh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Marchand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Claret</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Eppler</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ruppel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Abidoye</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>WT</given-names></string-name>, <string-name name-style="western"><surname>Dayog</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma</article-title>. <source>Clin Pharmacol Ther</source>. <year>2017</year>;<volume>102</volume>(<issue>2</issue>):<fpage>305</fpage>&#8211;<lpage>312</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.587</pub-id>.<pub-id pub-id-type="pmid">27981577</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>J-F</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Eppler</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Novotny</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lum</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gaudreault</surname><given-names>J</given-names></string-name></person-group>. <article-title>Clinical pharmacokinetics of bevacizumab in patients with solid tumors</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2008</year>;<volume>62</volume>(<issue>5</issue>):<fpage>779</fpage>&#8211;<lpage>786</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-007-0664-8</pub-id>.<pub-id pub-id-type="pmid">18205003</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vetter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vermeulen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Feagan</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Sands</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Pan&#233;s</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Combination therapy with guselkumab and golimumab in patients with moderately to severely active ulcerative colitis: pharmacokinetics, immunogenicity and drug&#8211;drug interactions</article-title>. <source>Clin Pharmacol Ther</source>. <year>2024</year>;<volume>115</volume>(<issue>6</issue>):<fpage>1418</fpage>&#8211;<lpage>1427</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.3235</pub-id>.<pub-id pub-id-type="pmid">38488354</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Candelaria</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez G&#243;mez</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Paravisini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Del Campo Garc&#237;a</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Miguel-Lillo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mill&#225;n</surname><given-names>S</given-names></string-name></person-group>. <article-title>Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83&#8482;, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2018</year>;<volume>81</volume>(<issue>3</issue>):<fpage>515</fpage>&#8211;<lpage>527</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-018-3524-9</pub-id>.<pub-id pub-id-type="pmid">29362903</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haddish&#8208;Berhane</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Russu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thayu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Knoblauch</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gibbs</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y-N</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Determination and confirmation of recommended Ph2 dose of amivantamab in epidermal growth factor receptor exon 20 insertion non&#8208;small cell lung cancer</article-title>. <source>Clin Pharmacol Ther</source>. <year>2024</year>;<volume>115</volume>(<issue>3</issue>):<fpage>468</fpage>&#8211;<lpage>477</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.3064</pub-id>.<pub-id pub-id-type="pmid">37776107</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>D</given-names></string-name>, et al</person-group>. <article-title>Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study</article-title>. <source>Front Pharmacol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1197651</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2024.1197651</pub-id>.<pub-id pub-id-type="pmid">38595918</pub-id><pub-id pub-id-type="pmcid">PMC11002205</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fau</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>El&#8208;Cheikh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Brillac</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Koiwai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mace</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Campana</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Semiond</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>L</given-names></string-name></person-group>. <article-title>Drug&#8208;disease interaction and time&#8208;dependent population pharmacokinetics of isatuximab in relapsed/refractory multiple myeloma patients</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2020</year>;<volume>9</volume>(<issue>11</issue>):<fpage>649</fpage>&#8211;<lpage>658</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12561</pub-id>.<pub-id pub-id-type="pmcid">PMC7679075</pub-id><pub-id pub-id-type="pmid">33021075</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Monteleone</surname><given-names>JPR</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kleijn</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Bellanti</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pelto</surname><given-names>R</given-names></string-name></person-group>. <article-title>Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis</article-title>. <source>Front Neurol</source>. <year>2021</year>;<volume>12</volume>:<fpage>696385</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2021.696385</pub-id>.<pub-id pub-id-type="pmid">34795626</pub-id><pub-id pub-id-type="pmcid">PMC8594444</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kovalenko</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>DiCioccio</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ardeleanu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Soltys</surname><given-names>R</given-names></string-name></person-group>. <article-title>Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL&#8208;4R&#945;, in atopic dermatitis patients and normal volunteers</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2016</year>;<volume>5</volume>(<issue>11</issue>):<fpage>617</fpage>&#8211;<lpage>624</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12136</pub-id>.<pub-id pub-id-type="pmcid">PMC5655850</pub-id><pub-id pub-id-type="pmid">27778477</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luo</surname><given-names>M</given-names></string-name> (Melody), <string-name name-style="western"><surname>Usmani</surname><given-names>SZ</given-names></string-name>, <string-name name-style="western"><surname>Mateos</surname><given-names>M-V</given-names></string-name>, <string-name name-style="western"><surname>Nahi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chari</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>San&#8208;Miguel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Touzeau</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kaiser</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Carson</surname><given-names>R</given-names></string-name></person-group>. et al. <article-title>Exposure&#8208;response and population pharmacokinetic analyses of a novel subcutaneous formulation of daratumumab administered to multiple myeloma patients</article-title>. <source>J Clin Pharmacol</source>. <year>2021</year>;<volume>61</volume>(<issue>5</issue>):<fpage>614</fpage>&#8211;<lpage>627</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1771</pub-id>.<pub-id pub-id-type="pmid">33145788</pub-id><pub-id pub-id-type="pmcid">PMC8048619</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chia</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Santiago</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kuruvilla</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tummala</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Roskos</surname><given-names>L</given-names></string-name></person-group>. <article-title>Exposure&#8211;response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus</article-title>. <source>Rheumatology</source>. <year>2021</year>;<volume>60</volume>(<issue>12</issue>):<fpage>5854</fpage>&#8211;<lpage>5862</lpage>. doi: <pub-id pub-id-type="doi">10.1093/rheumatology/keab176</pub-id>.<pub-id pub-id-type="pmid">33629110</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baverel</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Roskos</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tatipalli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Stockman</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Taboada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vicini</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Horgan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Narwal</surname><given-names>R</given-names></string-name></person-group>. <article-title>Exposure&#8211;response analysis of overall survival for tremelimumab in unresectable malignant mesothelioma: the confounding effect of disease status</article-title>. <source>Clin Transl Sci</source>. <year>2019</year>;<volume>12</volume>(<issue>5</issue>):<fpage>450</fpage>&#8211;<lpage>458</lpage>. doi: <pub-id pub-id-type="doi">10.1111/cts.12633</pub-id>.<pub-id pub-id-type="pmid">30883000</pub-id><pub-id pub-id-type="pmcid">PMC6742946</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Puszkiel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bianconi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pasquiers</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Balakirouchenane</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Arrondeau</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boudou-Rouquette</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bretagne</surname><given-names>M-C</given-names></string-name>, <string-name name-style="western"><surname>Salem</surname><given-names>J-E</given-names></string-name>, <string-name name-style="western"><surname>Decl&#232;ves</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Vidal</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients</article-title>. <source>Br J Cancer</source>. <year>2024</year>;<volume>130</volume>(<issue>11</issue>):<fpage>1866</fpage>&#8211;<lpage>1874</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41416-024-02659-x</pub-id>.<pub-id pub-id-type="pmid">38532102</pub-id><pub-id pub-id-type="pmcid">PMC11130267</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bang</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Giaccone</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Im</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Bauer</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Nordstrom</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chichili</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>First-in-human phase 1 study of margetuximab (MGAH22), an fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors</article-title>. <source>Ann Oncol</source>. <year>2017</year>;<volume>28</volume>(<issue>4</issue>):<fpage>855</fpage>&#8211;<lpage>861</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdx002</pub-id>.<pub-id pub-id-type="pmid">28119295</pub-id><pub-id pub-id-type="pmcid">PMC6246722</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Flat dose regimen of toripalimab based on model-informed drug development approach</article-title>. <source>Front Pharmacol</source>. <year>2023</year>;<volume>13</volume>:<fpage>1069818</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2022.1069818</pub-id>.<pub-id pub-id-type="pmid">36712659</pub-id><pub-id pub-id-type="pmcid">PMC9880172</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tout</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gagez</surname><given-names>A-L</given-names></string-name>, <string-name name-style="western"><surname>Lepr&#234;tre</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gouilleux-Gruart</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Azzopardi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Delmer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mercier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ysebaert</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Laribi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Influence of FCGR3A-158V/F genotype and baseline CD20 antigen count on target-mediated elimination of rituximab in patients with chronic lymphocytic leukemia: a study of FILO group</article-title>. <source>Clin Pharmacokinet</source>. <year>2017</year>;<volume>56</volume>(<issue>6</issue>):<fpage>635</fpage>&#8211;<lpage>647</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-016-0470-8</pub-id>.<pub-id pub-id-type="pmid">27783363</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bernadou</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Campone</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Merlin</surname><given-names>J-L</given-names></string-name>, <string-name name-style="western"><surname>Gouilleux&#8208;Gruart</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bachelot</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lokiec</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rezai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Arnedos</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Di&#233;ras</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Jimenez</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non&#8208;metastatic breast cancer</article-title>. <source>Br J Clin Pharmacol</source>. <year>2016</year>;<volume>81</volume>(<issue>5</issue>):<fpage>941</fpage>&#8211;<lpage>948</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.12875</pub-id>.<pub-id pub-id-type="pmid">26714164</pub-id><pub-id pub-id-type="pmcid">PMC4834606</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dimelow</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>S</given-names></string-name></person-group>. <article-title>Inter&#8208;regional pharmacokinetics and exposure&#8211;response analyses of belimumab in patients with system lupus erythematosus</article-title>. <source>Br J Clin Pharmacol</source>. <year>2025</year>;<volume>91</volume>(<issue>2</issue>):<fpage>374</fpage>&#8211;<lpage>385</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.16263</pub-id>.<pub-id pub-id-type="pmid">39319366</pub-id><pub-id pub-id-type="pmcid">PMC11773103</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Le Tilly</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Gatault</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Baron</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bejan&#8208;Angoulvant</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>B&#252;chler</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Paintaud</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ternant</surname><given-names>D</given-names></string-name></person-group>. <article-title>Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target&#8208;mediated drug disposition model</article-title>. <source>Br J Clin Pharmacol</source>. <year>2022</year>;<volume>88</volume>(<issue>7</issue>):<fpage>3500</fpage>&#8211;<lpage>3505</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.15235</pub-id>.<pub-id pub-id-type="pmid">35043423</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chua</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Friedrich</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>XC</given-names></string-name></person-group>. <article-title>Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase III LUCENT studies</article-title>. <source>Clin Pharmacokinet</source>. <year>2023</year>;<volume>62</volume>(<issue>10</issue>):<fpage>1479</fpage>&#8211;<lpage>1491</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-023-01281-z</pub-id>.<pub-id pub-id-type="pmid">37610533</pub-id><pub-id pub-id-type="pmcid">PMC10520102</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibiansky</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Passey</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>M</given-names></string-name></person-group>. <article-title>Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2016</year>;<volume>43</volume>(<issue>3</issue>):<fpage>243</fpage>&#8211;<lpage>257</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10928-016-9469-x</pub-id>.<pub-id pub-id-type="pmid">26993283</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bathena</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Keidel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Miller-Moslin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Statkevich</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Suryawanshi</surname><given-names>S</given-names></string-name></person-group>. <article-title>Model-informed clinical pharmacology profile of a novel fixed-dose combination of nivolumab and relatlimab in adult and adolescent patients with solid tumors</article-title>. <source>Clin Cancer Res</source>. <year>2024</year>;<volume>30</volume>(<issue>14</issue>):<fpage>3050</fpage>&#8211;<lpage>3058</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-2396</pub-id>.<pub-id pub-id-type="pmid">38295151</pub-id><pub-id pub-id-type="pmcid">PMC11247312</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Masson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Parker</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Berman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name></person-group>. <article-title>Model&#8208;based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma</article-title>. <source>Br J Clin Pharmacol</source>. <year>2014</year>;<volume>78</volume>(<issue>1</issue>):<fpage>106</fpage>&#8211;<lpage>117</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.12323</pub-id>.<pub-id pub-id-type="pmid">24433434</pub-id><pub-id pub-id-type="pmcid">PMC4168385</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ide</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Imai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Vezina</surname><given-names>HE</given-names></string-name></person-group>. <article-title>Model&#8208;based determination of elotuzumab pharmacokinetics in Japanese patients with multiple myeloma incorporating time&#8208;varying M protein</article-title>. <source>J Clin Pharmacol</source>. <year>2021</year>;<volume>61</volume>(<issue>1</issue>):<fpage>64</fpage>&#8211;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1698</pub-id>.<pub-id pub-id-type="pmid">32656777</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sanghavi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Murthy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Aras</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Vezina</surname><given-names>H</given-names></string-name></person-group>. <article-title>Model&#8208;based dose selection of subcutaneous nivolumab in patients with advanced solid tumors</article-title>. <source>Clin Pharmacol Ther</source>. <year>2024</year>;<volume>115</volume>(<issue>3</issue>):<fpage>488</fpage>&#8211;<lpage>497</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.3148</pub-id>.<pub-id pub-id-type="pmid">38115195</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>J</given-names></string-name></person-group>. <article-title>Model&#8208;based population pharmacokinetic analysis of nivolumab in Chinese patients with Previously treated advanced solid tumors, including non&#8211;small cell lung cancer</article-title>. <source>J Clin Pharmacol</source>. <year>2019</year>;<volume>59</volume>(<issue>10</issue>):<fpage>1415</fpage>&#8211;<lpage>1424</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1432</pub-id>.<pub-id pub-id-type="pmid">31115908</pub-id><pub-id pub-id-type="pmcid">PMC6767401</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mentr&#233;</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kovarik</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gerbeau</surname><given-names>C</given-names></string-name></person-group>. <article-title>No title found</article-title>. <source>J Pharmacokinet Biopharm</source>. <year>1999</year>;<volume>27</volume>(<issue>2</issue>):<fpage>213</fpage>&#8211;<lpage>230</lpage>. doi: <pub-id pub-id-type="doi">10.1023/A:1020658023774</pub-id>.<pub-id pub-id-type="pmid">10567956</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ternant</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Monjanel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Venel</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Prunier&#8208;Aesch</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Arbion</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Colombat</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Paintaud</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gyan</surname><given-names>E</given-names></string-name></person-group>. <article-title>Nonlinear pharmacokinetics of rituximab in non&#8208;Hodgkin lymphomas: a pilot study</article-title>. <source>Br J Clin Pharmacol</source>. <year>2019</year>;<volume>85</volume>(<issue>9</issue>):<fpage>2002</fpage>&#8211;<lpage>2010</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.13991</pub-id>.<pub-id pub-id-type="pmid">31112622</pub-id><pub-id pub-id-type="pmcid">PMC6710546</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Almquist</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kuruvilla</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tummala</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>WI</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Roskos</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chia</surname><given-names>YL</given-names></string-name></person-group>. <article-title>Nonlinear population pharmacokinetics of anifrolumab in healthy volunteers and patients with systemic lupus erythematosus</article-title>. <source>J Clin Pharmacol</source>. <year>2022</year>;<volume>62</volume>(<issue>9</issue>):<fpage>1106</fpage>&#8211;<lpage>1120</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.2055</pub-id>.<pub-id pub-id-type="pmid">35383948</pub-id><pub-id pub-id-type="pmcid">PMC9540432</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibiansky</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Petry</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mercier</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>G&#252;nther</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Herman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kappos</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hauser</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Model</surname><given-names>F</given-names></string-name>, et al</person-group>. <article-title>Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO</article-title>. <source>Br J Clin Pharmacol</source>. <year>2021</year>;<volume>87</volume>(<issue>6</issue>):<fpage>2511</fpage>&#8211;<lpage>2520</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.14658</pub-id>.<pub-id pub-id-type="pmid">33202059</pub-id><pub-id pub-id-type="pmcid">PMC8247316</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dotan</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ron</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yanai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Becker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fishman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yahav</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ben Yehoyada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mould</surname><given-names>DR</given-names></string-name></person-group>. <article-title>Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study</article-title>. <source>Inflamm Bowel Dis</source>. <year>2014</year>;<volume>20</volume>(<issue>12</issue>):<fpage>2247</fpage>&#8211;<lpage>2259</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MIB.0000000000000212</pub-id>.<pub-id pub-id-type="pmid">25358062</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abdallah</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fettner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Douglass</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rowell</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Burmester</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Kivitz</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA</article-title>. <source>J Clin Pharmacol</source>. <year>2017</year>;<volume>57</volume>(<issue>4</issue>):<fpage>459</fpage>&#8211;<lpage>468</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.826</pub-id>.<pub-id pub-id-type="pmid">27599663</pub-id><pub-id pub-id-type="pmcid">PMC5363244</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Puchalski</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Prabhakar</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Jiao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Berns</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>HM</given-names></string-name></person-group>. <article-title>Pharmacokinetic and pharmacodynamic modeling of an anti&#8211;Interleukin-6 chimeric monoclonal antibody (Siltuximab) in patients with metastatic renal cell carcinoma</article-title>. <source>Clin Cancer Res</source>. <year>2010</year>;<volume>16</volume>(<issue>5</issue>):<fpage>1652</fpage>&#8211;<lpage>1661</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-2581</pub-id>.<pub-id pub-id-type="pmid">20179212</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ly</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Griffiths</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>van der Merwe</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Agoram</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Parnes</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Roskos</surname><given-names>L</given-names></string-name></person-group>. <article-title>Pharmacokinetic and pharmacodynamic modeling of tezepelumab to guide phase 3 dose selection for patients with severe asthma</article-title>. <source>J Clin Pharmacol</source>. <year>2021</year>;<volume>61</volume>(<issue>7</issue>):<fpage>901</fpage>&#8211;<lpage>912</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1803</pub-id>.<pub-id pub-id-type="pmid">33368307</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chakraborty</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Van</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Skerjanec</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Floch</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>UR</given-names></string-name>, <string-name name-style="western"><surname>Krammer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sunkara</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Howard</surname><given-names>D</given-names></string-name></person-group>. <article-title>Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis</article-title>. <source>J Clin Pharmacol</source>. <year>2013</year>;<volume>53</volume>(<issue>12</issue>):<fpage>1240</fpage>&#8211;<lpage>1251</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.162</pub-id>.<pub-id pub-id-type="pmid">24122883</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chakraborty</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tannenbaum</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rordorf</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Floch</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gram</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>S</given-names></string-name></person-group>. <article-title>Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1&#946; monoclonal antibody: Clin</article-title>. <source>Clin Pharmacokinet</source>. <year>2012</year>;<volume>51</volume>(<issue>6</issue>):<fpage>e1</fpage>&#8211;<lpage>e18</lpage>. doi: <pub-id pub-id-type="doi">10.2165/11599820-000000000-00000</pub-id>.<pub-id pub-id-type="pmid">22550964</pub-id><pub-id pub-id-type="pmcid">PMC3584253</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fasanmade</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Adedokun</surname><given-names>OJ</given-names></string-name>, <string-name name-style="western"><surname>Blank</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>HM</given-names></string-name></person-group>. <article-title>Pharmacokinetic properties of infliximab in children and adults with Crohn&#8217;s disease: a retrospective analysis of data from 2 phase III clinical trials</article-title>. <source>Clin Ther</source>. <year>2011</year>;<volume>33</volume>(<issue>7</issue>):<fpage>946</fpage>&#8211;<lpage>964</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clinthera.2011.06.002</pub-id>.<pub-id pub-id-type="pmid">21741088</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanzel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dreesen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vermeire</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>L&#246;wenberg</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hoentjen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bossuyt</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Clasquin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Baert</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Haens</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Math&#244;t</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Pharmacokinetic-pharmacodynamic model of vedolizumab for targeting endoscopic remission in patients with Crohn disease: posthoc analysis of the LOVE-CD study</article-title>. <source>Inflamm Bowel Dis</source>. <year>2022</year>;<volume>28</volume>(<issue>5</issue>):<fpage>689</fpage>&#8211;<lpage>699</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ibd/izab143</pub-id>.<pub-id pub-id-type="pmid">34137430</pub-id><pub-id pub-id-type="pmcid">PMC9071095</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>de Hoon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Van Hecken</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vargas</surname><given-names>G</given-names></string-name></person-group>. <article-title>Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects</article-title>. <source>Pharm Res</source>. <year>2017</year>;<volume>34</volume>(<issue>9</issue>):<fpage>1784</fpage>&#8211;<lpage>1795</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11095-017-2183-6</pub-id>.<pub-id pub-id-type="pmid">28593473</pub-id><pub-id pub-id-type="pmcid">PMC5533838</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chamberlain</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sile</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hammel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Holt</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Ramanathan</surname><given-names>S</given-names></string-name></person-group>. <article-title>Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody, in thyroid eye disease</article-title>. <source>Clin Pharmacokinet</source>. <year>2021</year>;<volume>60</volume>(<issue>8</issue>):<fpage>1029</fpage>&#8211;<lpage>1040</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-021-01003-3</pub-id>.<pub-id pub-id-type="pmid">33768488</pub-id><pub-id pub-id-type="pmcid">PMC8332554</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>XS</given-names></string-name>, <string-name name-style="western"><surname>Dimopoulos</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Sonneveld</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Belch</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Leiba</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Capra</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gomez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Medvedova</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Iida</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Pharmacokinetics and exposure&#8211;response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma</article-title>. <source>Adv Ther</source>. <year>2018</year>;<volume>35</volume>(<issue>11</issue>):<fpage>1859</fpage>&#8211;<lpage>1872</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12325-018-0815-9</pub-id>.<pub-id pub-id-type="pmid">30374808</pub-id><pub-id pub-id-type="pmcid">PMC6223994</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khatri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Eckert</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Oberoi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Suleiman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Othman</surname><given-names>AA</given-names></string-name></person-group>. <article-title>Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis</article-title>. <source>J Clin Pharmacol</source>. <year>2019</year>;<volume>59</volume>(<issue>12</issue>):<fpage>1656</fpage>&#8211;<lpage>1668</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1473</pub-id>.<pub-id pub-id-type="pmid">31257614</pub-id><pub-id pub-id-type="pmcid">PMC6852105</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blasco</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chatelut</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>De Bretagne</surname><given-names>IB</given-names></string-name>, <string-name name-style="western"><surname>Congy&#8208;Jolivet</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Le Guellec</surname><given-names>C</given-names></string-name></person-group>. <article-title>Pharmacokinetics of rituximab associated with CHOP chemotherapy in B&#8208;cell non&#8208;Hodgkin lymphoma</article-title>. <source>Fundam Clin Pharmacol</source>. <year>2009</year>;<volume>23</volume>(<issue>5</issue>):<fpage>601</fpage>&#8211;<lpage>608</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1472-8206.2009.00714.x</pub-id>.<pub-id pub-id-type="pmid">19659797</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baverel</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stelmach</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>She</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Agoram</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sandbach</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Piper</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kuna</surname><given-names>P</given-names></string-name></person-group>. <article-title>Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing</article-title>. <source>Br J Clin Pharmacol</source>. <year>2015</year>;<volume>80</volume>(<issue>6</issue>):<fpage>1337</fpage>&#8211;<lpage>1349</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.12725</pub-id>.<pub-id pub-id-type="pmid">26182954</pub-id><pub-id pub-id-type="pmcid">PMC4693499</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibiansky</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gibiansky</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Buchheit</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Frey</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Brewster</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fingerle&#8208;Rowson</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jamois</surname><given-names>C</given-names></string-name></person-group>. <article-title>Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab&#8208;refractory follicular lymphoma patients in the GADOLIN phase III study</article-title>. <source>Br J Clin Pharmacol</source>. <year>2019</year>;<volume>85</volume>(<issue>9</issue>):<fpage>1935</fpage>&#8211;<lpage>1945</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.13974</pub-id>.<pub-id pub-id-type="pmid">31050355</pub-id><pub-id pub-id-type="pmcid">PMC6710522</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koiwai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>El&#8208;Cheikh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Thai</surname><given-names>H-T</given-names></string-name>, <string-name name-style="western"><surname>Brillac</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fau</surname><given-names>J-B</given-names></string-name>, <string-name name-style="western"><surname>Veyrat&#8208;Follet</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Risse</surname><given-names>M-L</given-names></string-name>, <string-name name-style="western"><surname>van de Velde</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Semiond</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2021</year>;<volume>10</volume>(<issue>8</issue>):<fpage>928</fpage>&#8211;<lpage>940</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12666</pub-id>.<pub-id pub-id-type="pmcid">PMC8376141</pub-id><pub-id pub-id-type="pmid">34185964</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>K-J</given-names></string-name>, <string-name name-style="western"><surname>Mendell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Harnisch</surname><given-names>LO</given-names></string-name></person-group>. <article-title>Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2024</year>;<volume>51</volume>(<issue>6</issue>):<fpage>905</fpage>&#8211;<lpage>917</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10928-024-09941-8</pub-id>.<pub-id pub-id-type="pmid">39349796</pub-id><pub-id pub-id-type="pmcid">PMC11579122</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Martinez</surname><given-names>J-M</given-names></string-name>, <string-name name-style="western"><surname>Brunet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hurbin</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>DiCioccio</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Rauch</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fabre</surname><given-names>D</given-names></string-name></person-group>. <article-title>Population pharmacokinetic analysis of alirocumab in healthy volunteers or hypercholesterolemic subjects using a Michaelis&#8211;menten approximation of a target-mediated drug disposition model&#8212;support for a biologics license application submission: part I</article-title>. <source>Clin Pharmacokinet</source>. <year>2019</year>;<volume>58</volume>(<issue>1</issue>):<fpage>101</fpage>&#8211;<lpage>113</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-018-0669-y</pub-id>.<pub-id pub-id-type="pmid">29725996</pub-id><pub-id pub-id-type="pmcid">PMC6325993</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibiansky</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sutjandra</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Doshi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sohn</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Jang</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Ruixo</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours: Clin</article-title>. <source>Pharmacokinet</source>. <year>2012</year>;<volume>51</volume>(<issue>4</issue>):<fpage>247</fpage>&#8211;<lpage>260</lpage>. doi: <pub-id pub-id-type="doi">10.2165/11598090-000000000-00000</pub-id>.<pub-id pub-id-type="pmid">22420579</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Kanamaluru</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Q</given-names></string-name></person-group>. <article-title>Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2021</year>;<volume>10</volume>(<issue>8</issue>):<fpage>941</fpage>&#8211;<lpage>952</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12667</pub-id>.<pub-id pub-id-type="pmcid">PMC8376131</pub-id><pub-id pub-id-type="pmid">34313019</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fasanmade</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Adedokun</surname><given-names>OJ</given-names></string-name>, <string-name name-style="western"><surname>Ford</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hernandez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Johanns</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name></person-group>. <article-title>Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2009</year>;<volume>65</volume>(<issue>12</issue>):<fpage>1211</fpage>&#8211;<lpage>1228</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00228-009-0718-4</pub-id>.<pub-id pub-id-type="pmid">19756557</pub-id><pub-id pub-id-type="pmcid">PMC2778780</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ma</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>B-B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y-M</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Narayanan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sutjandra</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>A</given-names></string-name></person-group>. <article-title>Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors</article-title>. <source>J Clin Pharmacol</source>. <year>2009</year>;<volume>49</volume>(<issue>10</issue>):<fpage>1142</fpage>&#8211;<lpage>1156</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0091270009344989</pub-id>.<pub-id pub-id-type="pmid">19723673</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frey</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Grange</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Woodworth</surname><given-names>T</given-names></string-name></person-group>. <article-title>Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis</article-title>. <source>J Clin Pharmacol</source>. <year>2010</year>;<volume>50</volume>(<issue>7</issue>):<fpage>754</fpage>&#8211;<lpage>766</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0091270009350623</pub-id>.<pub-id pub-id-type="pmid">20097931</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quartino</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kirschbrown</surname><given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Mangat</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wada</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Lum</surname><given-names>B</given-names></string-name></person-group>. <article-title>Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin&#174;), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2019</year>;<volume>83</volume>(<issue>2</issue>):<fpage>329</fpage>&#8211;<lpage>340</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-018-3728-z</pub-id>.<pub-id pub-id-type="pmid">30467591</pub-id><pub-id pub-id-type="pmcid">PMC6394489</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garg</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Quartino</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wada</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cort&#233;s</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McNally</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Visich</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2014</year>;<volume>74</volume>(<issue>4</issue>):<fpage>819</fpage>&#8211;<lpage>829</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-014-2560-3</pub-id>.<pub-id pub-id-type="pmid">25119184</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hennig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Badovinac Crnjevic</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kaewphluk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>K&#229;gedal</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Quartino</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Girish</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kirschbrown</surname><given-names>WP</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetic and exploratory exposure&#8211;response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2021</year>;<volume>88</volume>(<issue>3</issue>):<fpage>499</fpage>&#8211;<lpage>512</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-021-04296-0</pub-id>.<pub-id pub-id-type="pmid">34106303</pub-id><pub-id pub-id-type="pmcid">PMC8187458</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibiansky</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gibiansky</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chavanne</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Frey</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Jamois</surname><given-names>C</given-names></string-name></person-group>. <article-title>Population pharmacokinetic and exposure&#8211;response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2021</year>;<volume>10</volume>(<issue>8</issue>):<fpage>914</fpage>&#8211;<lpage>927</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12665</pub-id>.<pub-id pub-id-type="pmcid">PMC8376135</pub-id><pub-id pub-id-type="pmid">34110098</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quartino</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Hillenbach</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wada</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Visich</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Heinzmann</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Lum</surname><given-names>BL</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetic and exposure&#8211;response analysis for trastuzumab administered using a subcutaneous &#8220;manual syringe&#8221; injection or intravenously in women with HER2-positive early breast cancer</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2016</year>;<volume>77</volume>(<issue>1</issue>):<fpage>77</fpage>&#8211;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-015-2922-5</pub-id>.<pub-id pub-id-type="pmid">26645407</pub-id><pub-id pub-id-type="pmcid">PMC4706584</pub-id></mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thakre</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Goebel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Winzenborg</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Suleiman</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Cunha</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mensing</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Population pharmacokinetic and exposure&#8211;response modeling to inform risankizumab dose selection in patients with ulcerative colitis</article-title>. <source>Clin Pharmacol Ther</source>. <year>2024</year>;<volume>116</volume>(<issue>3</issue>):<fpage>847</fpage>&#8211;<lpage>857</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.3330</pub-id>.<pub-id pub-id-type="pmid">38863178</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Struemper</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Thapar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Roth</surname><given-names>D</given-names></string-name></person-group>. <article-title>Population pharmacokinetic and pharmacodynamic analysis of belimumab administered subcutaneously in healthy volunteers and patients with systemic lupus erythematosus</article-title>. <source>Clin Pharmacokinet</source>. <year>2018</year>;<volume>57</volume>(<issue>6</issue>):<fpage>717</fpage>&#8211;<lpage>728</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-017-0586-5</pub-id>.<pub-id pub-id-type="pmid">28887801</pub-id><pub-id pub-id-type="pmcid">PMC5973992</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>K-S</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Pavlov</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Parivar</surname><given-names>K</given-names></string-name></person-group>. <article-title>Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma</article-title>. <source>J Clin Pharmacol</source>. <year>2014</year>;<volume>54</volume>(<issue>10</issue>):<fpage>1108</fpage>&#8211;<lpage>1116</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.309</pub-id>.<pub-id pub-id-type="pmid">24737343</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Passarell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jaworowicz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ludwig</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Rabinovich&#8208;Guilatt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Levi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Garin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fiedler&#8208;Kelly</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bond</surname><given-names>M</given-names></string-name></person-group>. <article-title>Population pharmacokinetic and pharmacokinetic/pharmacodynamic modeling of weight&#8208;based intravenous reslizumab dosing</article-title>. <source>J Clin Pharmacol</source>. <year>2020</year>;<volume>60</volume>(<issue>8</issue>):<fpage>1039</fpage>&#8211;<lpage>1050</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1609</pub-id>.<pub-id pub-id-type="pmid">32333684</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Paccaly</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Rippley</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>DiCioccio</surname><given-names>AT</given-names></string-name></person-group>. <article-title>Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2021</year>;<volume>48</volume>(<issue>4</issue>):<fpage>479</fpage>&#8211;<lpage>494</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10928-021-09739-y</pub-id>.<pub-id pub-id-type="pmid">33728546</pub-id><pub-id pub-id-type="pmcid">PMC8225544</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sutjandra</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Doshi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Jang</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Chow</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Ruixo</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis: Clin</article-title>. <source>Pharmacokinet</source>. <year>2011</year>;<volume>50</volume>(<issue>12</issue>):<fpage>793</fpage>&#8211;<lpage>807</lpage>. doi: <pub-id pub-id-type="doi">10.2165/11594240-000000000-00000</pub-id>.<pub-id pub-id-type="pmid">22087866</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Brien</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Westwood</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Heathman</surname><given-names>M</given-names></string-name></person-group>. <article-title>Population pharmacokinetic meta&#8208;analysis of ramucirumab in cancer patients</article-title>. <source>Br J Clin Pharmacol</source>. <year>2017</year>;<volume>83</volume>(<issue>12</issue>):<fpage>2741</fpage>&#8211;<lpage>2751</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.13403</pub-id>.<pub-id pub-id-type="pmid">28833321</pub-id><pub-id pub-id-type="pmcid">PMC5698573</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Abuqayyas</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Quartino</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hellqvist</surname><given-names>&#197;</given-names></string-name>, <string-name name-style="western"><surname>Colice</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>MacDonald</surname><given-names>A</given-names></string-name></person-group>. <article-title>Population pharmacokinetic modeling and exposure&#8211;efficacy and body weight&#8211;response analyses for tezepelumab in patients with severe, uncontrolled asthma</article-title>. <source>J Clin Pharmacol</source>. <year>2024</year>;<volume>64</volume>(<issue>8</issue>):<fpage>908</fpage>&#8211;<lpage>921</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.2433</pub-id>.<pub-id pub-id-type="pmid">38632826</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chia</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Roskos</surname><given-names>LK</given-names></string-name></person-group>. <article-title>Population pharmacokinetic modeling of benralizumab in adult and adolescent patients with asthma</article-title>. <source>Clin Pharmacokinet</source>. <year>2019</year>;<volume>58</volume>(<issue>7</issue>):<fpage>943</fpage>&#8211;<lpage>958</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-019-00738-4</pub-id>.<pub-id pub-id-type="pmid">30854591</pub-id><pub-id pub-id-type="pmcid">PMC6584252</pub-id></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kimko</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cimbora</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Rees</surname><given-names>WA</given-names></string-name></person-group>. <article-title>Population pharmacokinetic modeling of inebilizumab in subjects with neuromyelitis optica spectrum disorders, systemic sclerosis, or relapsing multiple sclerosis</article-title>. <source>Clin Pharmacokinet</source>. <year>2022</year>;<volume>61</volume>(<issue>3</issue>):<fpage>387</fpage>&#8211;<lpage>400</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-021-01071-5</pub-id>.<pub-id pub-id-type="pmid">34718986</pub-id><pub-id pub-id-type="pmcid">PMC8891208</pub-id></mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mukai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maeda</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Narushima</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mould</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Greene</surname><given-names>D</given-names></string-name></person-group>. <article-title>Population pharmacokinetic modeling of mogamulizumab in adults with cutaneous T&#8208;cell lymphoma or adult T&#8208;cell lymphoma</article-title>. <source>J Clin Pharmacol</source>. <year>2020</year>;<volume>60</volume>(<issue>1</issue>):<fpage>58</fpage>&#8211;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1564</pub-id>.<pub-id pub-id-type="pmid">31840838</pub-id></mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Baldwin</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Luffer-Atlas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ilaria</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Conti</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Heathman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cronier</surname><given-names>DM</given-names></string-name></person-group>. <article-title>Population pharmacokinetic modeling of olaratumab, an anti-PDGFR&#945; human monoclonal antibody, in patients with advanced and/or metastatic cancer</article-title>. <source>Clin Pharmacokinet</source>. <year>2018</year>;<volume>57</volume>(<issue>3</issue>):<fpage>355</fpage>&#8211;<lpage>365</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-017-0562-0</pub-id>.<pub-id pub-id-type="pmid">28620891</pub-id><pub-id pub-id-type="pmcid">PMC5814542</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>CSW</given-names></string-name>, <string-name name-style="western"><surname>Sweeney</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cronenberger</surname><given-names>C</given-names></string-name></person-group>. <article-title>Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin&#174;) in patients with advanced non-squamous non-small cell lung cancer</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2020</year>;<volume>85</volume>(<issue>3</issue>):<fpage>487</fpage>&#8211;<lpage>499</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-019-03946-8</pub-id>.<pub-id pub-id-type="pmid">31768697</pub-id><pub-id pub-id-type="pmcid">PMC7036079</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bruin</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Loesche</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nyirady</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sander</surname><given-names>O</given-names></string-name></person-group>. <article-title>Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis</article-title>. <source>J Clin Pharmacol</source>. <year>2017</year>;<volume>57</volume>(<issue>7</issue>):<fpage>876</fpage>&#8211;<lpage>885</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.876</pub-id>.<pub-id pub-id-type="pmid">28273356</pub-id><pub-id pub-id-type="pmcid">PMC5485066</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Waterhouse</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Baron</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Eure</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dirks</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Jansson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Akbari</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mehrotra</surname><given-names>S</given-names></string-name></person-group>. <article-title>Population pharmacokinetic modeling of vedolizumab for graft&#8208;versus&#8208;host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant</article-title>. <source>Pharmacol Res &amp; Perspect</source>. <year>2024</year>;<volume>12</volume>(<issue>5</issue>):<fpage>e1257</fpage>. doi: <pub-id pub-id-type="doi">10.1002/prp2.1257</pub-id>.<pub-id pub-id-type="pmid">39233318</pub-id><pub-id pub-id-type="pmcid">PMC11374527</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hwang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chia</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>CCK</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Goldberg</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Siu</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Planchard</surname><given-names>D</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time&#8208;varying clearance</article-title>. <source>Br J Clin Pharmacol</source>. <year>2023</year>;<volume>89</volume>(<issue>5</issue>):<fpage>1601</fpage>&#8211;<lpage>1616</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.15622</pub-id>.<pub-id pub-id-type="pmid">36454221</pub-id></mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hayato</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Takenaka</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Sreerama Reddy</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Landry</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Reyderman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Koyama</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yasuda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hussein</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Population pharmacokinetic&#8208;pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer&#8217;s disease</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2022</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1578</fpage>&#8211;<lpage>1591</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12862</pub-id>.<pub-id pub-id-type="pmcid">PMC9755918</pub-id><pub-id pub-id-type="pmid">36165093</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Verstockt</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sabino</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vermeire</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ferrante</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Declerck</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dreesen</surname><given-names>E</given-names></string-name></person-group>. <article-title>Population pharmacokinetic&#8208;pharmacodynamic model&#8208;based exploration of alternative ustekinumab dosage regimens for patients with Crohn&#8217;s disease</article-title>. <source>Br J Clin Pharmacol</source>. <year>2022</year>;<volume>88</volume>(<issue>1</issue>):<fpage>323</fpage>&#8211;<lpage>335</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.14971</pub-id>.<pub-id pub-id-type="pmid">34197653</pub-id></mixed-citation></ref><ref id="cit0114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>David</surname><given-names>OJ</given-names></string-name>, <string-name name-style="western"><surname>Kahn</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Savelieva</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pigeolet</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Das Gupta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pingili</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Willi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ramanathan</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetic&#8211;B cell modeling for ofatumumab in patients with relapsing multiple sclerosis</article-title>. <source>CNS Drugs</source>. <year>2022</year>;<volume>36</volume>(<issue>3</issue>):<fpage>283</fpage>&#8211;<lpage>300</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40263-021-00895-w</pub-id>.<pub-id pub-id-type="pmid">35233753</pub-id><pub-id pub-id-type="pmcid">PMC8927028</pub-id></mixed-citation></ref><ref id="cit0115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name></person-group>. <article-title>Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2024</year>;<volume>80</volume>(<issue>9</issue>):<fpage>1325</fpage>&#8211;<lpage>1338</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00228-024-03703-8</pub-id>.<pub-id pub-id-type="pmid">38814441</pub-id><pub-id pub-id-type="pmcid">PMC11303580</pub-id></mixed-citation></ref><ref id="cit0116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tran</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Vermeulen</surname><given-names>A</given-names></string-name></person-group>. <article-title>Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis</article-title>. <source>Br J Clin Pharmacol</source>. <year>2022</year>;<volume>88</volume>(<issue>10</issue>):<fpage>4481</fpage>&#8211;<lpage>4493</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.15364</pub-id>.<pub-id pub-id-type="pmid">35470450</pub-id></mixed-citation></ref><ref id="cit0117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Osawa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hasegawa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hruska</surname><given-names>MW</given-names></string-name></person-group>. <article-title>Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2019</year>;<volume>83</volume>(<issue>4</issue>):<fpage>705</fpage>&#8211;<lpage>715</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-019-03771-z</pub-id>.<pub-id pub-id-type="pmid">30666395</pub-id></mixed-citation></ref><ref id="cit0118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ludwig</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Passarell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hruska</surname><given-names>MW</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and exposure &#8212; safety analyses of nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma</article-title>. <source>J Clin Pharmacol</source>. <year>2019</year>;<volume>59</volume>(<issue>3</issue>):<fpage>364</fpage>&#8211;<lpage>373</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1324</pub-id>.<pub-id pub-id-type="pmid">30339279</pub-id></mixed-citation></ref><ref id="cit0119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Adedokun</surname><given-names>OJ</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and exposure&#8208;response modeling analyses of ustekinumab in adults with moderately to severely active ulcerative colitis</article-title>. <source>J Clin Pharmacol</source>. <year>2020</year>;<volume>60</volume>(<issue>7</issue>):<fpage>889</fpage>&#8211;<lpage>902</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.1582</pub-id>.<pub-id pub-id-type="pmid">32026499</pub-id></mixed-citation></ref><ref id="cit0120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thakre</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Cunha</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Goebel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Suleiman</surname><given-names>AA</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response analyses for risankizumab in patients with active psoriatic arthritis</article-title>. <source>Rheumatol Ther</source>. <year>2022</year>;<volume>9</volume>(<issue>6</issue>):<fpage>1587</fpage>&#8211;<lpage>1603</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40744-022-00495-0</pub-id>.<pub-id pub-id-type="pmid">36178584</pub-id><pub-id pub-id-type="pmcid">PMC9561470</pub-id></mixed-citation></ref><ref id="cit0121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dosne</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Nnane</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Dimopoulos</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Terpos</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sonneveld</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kampfenkel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Carson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Amin</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma</article-title>. <source>Br J Clin Pharmacol</source>. <year>2023</year>;<volume>89</volume>(<issue>5</issue>):<fpage>1640</fpage>&#8211;<lpage>1655</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.15628</pub-id>.<pub-id pub-id-type="pmid">36484341</pub-id></mixed-citation></ref><ref id="cit0122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Majid</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Willis</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Hayato</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Takenaka</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Lalovic</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sreerama Reddy</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Penner</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Reyderman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yasuda</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response analyses of safety (ARIA -E and isolated ARIA -H) of lecanemab in subjects with early Alzheimer&#8217;s disease</article-title>. <source>CPT Pharmacom &amp; Syst Pharma</source>. <year>2024</year>;<volume>13</volume>(<issue>12</issue>):<fpage>2111</fpage>&#8211;<lpage>2123</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.13224</pub-id>.<pub-id pub-id-type="pmcid">PMC11646937</pub-id><pub-id pub-id-type="pmid">39207112</pub-id></mixed-citation></ref><ref id="cit0123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cosson</surname><given-names>VF</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>VW</given-names></string-name>, <string-name name-style="western"><surname>Lehle</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lum</surname><given-names>BL</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2014</year>;<volume>73</volume>(<issue>4</issue>):<fpage>737</fpage>&#8211;<lpage>747</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-014-2400-5</pub-id>.<pub-id pub-id-type="pmid">24519752</pub-id></mixed-citation></ref><ref id="cit0124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adedokun</surname><given-names>OJ</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gasink</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kowalski</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sandborn</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Feagan</surname><given-names>B</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response analyses of ustekinumab in patients with moderately to severely active Crohn&#8217;s disease</article-title>. <source>Clinical Therapeutics</source>. <year>2022</year>;<volume>44</volume>(<issue>10</issue>):<fpage>1336</fpage>&#8211;<lpage>1355</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clinthera.2022.08.010</pub-id>.<pub-id pub-id-type="pmid">36150926</pub-id></mixed-citation></ref><ref id="cit0125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>JZ</given-names></string-name>, <string-name name-style="western"><surname>Duval</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Jauslin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abegesah</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response analysis for the CTLA&#8208;4 inhibitor tremelimumab in metastatic NSCLC patients in the phase III POSEIDON study</article-title>. <source>Clin Pharmacol &amp; Ther</source>. <year>2023</year>;<volume>114</volume>(<issue>6</issue>):<fpage>1375</fpage>&#8211;<lpage>1386</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.3063</pub-id>.<pub-id pub-id-type="pmid">37777827</pub-id></mixed-citation></ref><ref id="cit0126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lim</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Abegesah</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>JZ</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Negro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Makowsky</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response analysis of tremelimumab 300 mg single dose combined with durvalumab 1500 mg Q4W (STRIDE) in patients with unresectable hepatocellular carcinoma</article-title>. <source>J Clin Pharmacol</source>. <year>2023</year>;<volume>63</volume>(<issue>11</issue>):<fpage>1221</fpage>&#8211;<lpage>1231</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.2288</pub-id>.<pub-id pub-id-type="pmid">37300457</pub-id></mixed-citation></ref><ref id="cit0127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sale</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Al&#8208;Huniti</surname><given-names>N</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response modeling for evinacumab in homozygous familial hypercholesterolemia</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2021</year>;<volume>10</volume>(<issue>11</issue>):<fpage>1412</fpage>&#8211;<lpage>1421</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12711</pub-id>.<pub-id pub-id-type="pmcid">PMC8592514</pub-id><pub-id pub-id-type="pmid">34585515</pub-id></mixed-citation></ref><ref id="cit0128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Adedokun</surname><given-names>OJ</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Reinisch</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Feagan</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Sandborn</surname><given-names>WJ</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response modeling of golimumab in adults with moderately to severely active ulcerative colitis</article-title>. <source>Clin Ther</source>. <year>2020</year>;<volume>42</volume>(<issue>1</issue>):<fpage>157</fpage>&#8211;<lpage>174.e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clinthera.2019.11.010</pub-id>.<pub-id pub-id-type="pmid">31982148</pub-id></mixed-citation></ref><ref id="cit0129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Melhem</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hanze</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Alsk&#228;r</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Visser</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gandhi</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response of anti&#8208;programmed cell death protein&#8208;1 monoclonal antibody dostarlimab in advanced solid tumours</article-title>. <source>Br J Clin Pharmacol</source>. <year>2022</year>;<volume>88</volume>(<issue>9</issue>):<fpage>4142</fpage>&#8211;<lpage>4154</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.15339</pub-id>.<pub-id pub-id-type="pmid">35357027</pub-id><pub-id pub-id-type="pmcid">PMC9543385</pub-id></mixed-citation></ref><ref id="cit0130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuchimanchi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>J&#248;rgensen</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Hanze</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Andr&#233;</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Berton</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Alsk&#228;r</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Zub</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Oaknin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shahin</surname><given-names>MS</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics and exposure&#8211;response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY</article-title>. <source>Br J Clin Pharmacol</source>. <year>2024</year>;<volume>91</volume>(<issue>3</issue>):p.<fpage>841</fpage>&#8211;<lpage>855</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.16325</pub-id>.<pub-id pub-id-type="pmid">39520048</pub-id><pub-id pub-id-type="pmcid">PMC11862793</pub-id></mixed-citation></ref><ref id="cit0131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Roskos</surname><given-names>L</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and patients with asthma</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2017</year>;<volume>6</volume>(<issue>4</issue>):<fpage>249</fpage>&#8211;<lpage>257</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12160</pub-id>.<pub-id pub-id-type="pmcid">PMC5397562</pub-id><pub-id pub-id-type="pmid">28109128</pub-id></mixed-citation></ref><ref id="cit0132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yee</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Kleijn</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Kerbusch</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Matthews</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Dorr</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Garey</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Wrishko</surname><given-names>RE</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and pharmacodynamics of bezlotoxumab in adults with primary and recurrent clostridium difficile infection</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2019</year>;<volume>63</volume>(<issue>2</issue>):<fpage>e01971</fpage>&#8211;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01971-18</pub-id>.<pub-id pub-id-type="pmid">30455246</pub-id><pub-id pub-id-type="pmcid">PMC6355577</pub-id></mixed-citation></ref><ref id="cit0133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kandadi Muralidharan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kowalski</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Rajagovindan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Budd Haberlain</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nestorov</surname><given-names>I</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque&#8211;removing agent, in patients with Alzheimer&#8217;s disease</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2022</year>;<volume>11</volume>(<issue>1</issue>):<fpage>7</fpage>&#8211;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12728</pub-id>.<pub-id pub-id-type="pmcid">PMC8752104</pub-id><pub-id pub-id-type="pmid">34697913</pub-id></mixed-citation></ref><ref id="cit0134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Muralidharan</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Kuesters</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Plavina</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Subramanyam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mikol</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Gopal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nestorov</surname><given-names>I</given-names></string-name></person-group>. <article-title>Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis</article-title>. <source>J Clin Pharmacol</source>. <year>2017</year>;<volume>57</volume>(<issue>8</issue>):<fpage>1017</fpage>&#8211;<lpage>1030</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.894</pub-id>.<pub-id pub-id-type="pmid">28398628</pub-id></mixed-citation></ref><ref id="cit0135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nguyen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Epling</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dolphin</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Paccaly</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Conrado</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Al&#8208;Huniti</surname><given-names>N</given-names></string-name></person-group>. <article-title>Population pharmacokinetics modeling and exposure&#8208;response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2022</year>;<volume>11</volume>(<issue>11</issue>):<fpage>1458</fpage>&#8211;<lpage>1471</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12855</pub-id>.<pub-id pub-id-type="pmcid">PMC9662200</pub-id><pub-id pub-id-type="pmid">36251220</pub-id></mixed-citation></ref><ref id="cit0136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ogasawara</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Newhall</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Maxwell</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Dell&#8217;aringa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Komashko</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kilavuz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Delarue</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Czuczman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sternas</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rose</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics of an anti-PD-L1 antibody, durvalumab in patients with hematologic malignancies</article-title>. <source>Clin Pharmacokinet</source>. <year>2020</year>;<volume>59</volume>(<issue>2</issue>):<fpage>217</fpage>&#8211;<lpage>227</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-019-00804-x</pub-id>.<pub-id pub-id-type="pmid">31332669</pub-id><pub-id pub-id-type="pmcid">PMC7007418</pub-id></mixed-citation></ref><ref id="cit0137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Struemper</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>W</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus</article-title>. <source>J Clin Pharmacol</source>. <year>2013</year>;<volume>53</volume>(<issue>7</issue>):<fpage>711</fpage>&#8211;<lpage>720</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.104</pub-id>.<pub-id pub-id-type="pmid">23681782</pub-id></mixed-citation></ref><ref id="cit0138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Han</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Peyret</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Marchand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Quartino</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gosselin</surname><given-names>NH</given-names></string-name>, <string-name name-style="western"><surname>Girish</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Allison</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>J</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of bevacizumab in cancer patients with external validation</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2016</year>;<volume>78</volume>(<issue>2</issue>):<fpage>341</fpage>&#8211;<lpage>351</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-016-3079-6</pub-id>.<pub-id pub-id-type="pmid">27329360</pub-id><pub-id pub-id-type="pmcid">PMC4965493</pub-id></mixed-citation></ref><ref id="cit0139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Endres</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Salinger</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>K&#246;ck</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gastonguay</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Klekotka</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Nirula</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gibbs</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies</article-title>. <source>J Clin Pharmacol</source>. <year>2014</year>;<volume>54</volume>(<issue>11</issue>):<fpage>1230</fpage>&#8211;<lpage>1238</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.334</pub-id>.<pub-id pub-id-type="pmid">24846347</pub-id></mixed-citation></ref><ref id="cit0140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Timmermann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>A</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. <year>2019</year>;<volume>125</volume>(<issue>1</issue>):<fpage>16</fpage>&#8211;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcpt.13202</pub-id>.<pub-id pub-id-type="pmid">30661290</pub-id><pub-id pub-id-type="pmcid">PMC6850607</pub-id></mixed-citation></ref><ref id="cit0141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>K-J</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Rosario</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Harnisch</surname><given-names>LO</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>DiCioccio</surname><given-names>AT</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of casirivimab and imdevimab in pediatric and adult non-infected individuals, pediatric and adult ambulatory or hospitalized patients or household contacts of patients infected with SARS-COV-2</article-title>. <source>Pharm Res</source>. <year>2024</year>;<volume>41</volume>(<issue>10</issue>):<fpage>1933</fpage>&#8211;<lpage>1949</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11095-024-03764-5</pub-id>.<pub-id pub-id-type="pmid">39294447</pub-id><pub-id pub-id-type="pmcid">PMC11530482</pub-id></mixed-citation></ref><ref id="cit0142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Seitz</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fasanmade</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ford</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Williamson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of infliximab in patients with ankylosing spondylitis</article-title>. <source>J Clin Pharmacol</source>. <year>2008</year>;<volume>48</volume>(<issue>6</issue>):<fpage>681</fpage>&#8211;<lpage>695</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0091270008316886</pub-id>.<pub-id pub-id-type="pmid">18401017</pub-id></mixed-citation></ref><ref id="cit0143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buurman</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Maurer</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Keizer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Kosterink</surname><given-names>JGW</given-names></string-name>, <string-name name-style="western"><surname>Dijkstra</surname><given-names>G</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice</article-title>. <source>Alimentary Pharmacol &amp; Ther</source>. <year>2015</year>;<volume>42</volume>(<issue>5</issue>):<fpage>529</fpage>&#8211;<lpage>539</lpage>. doi: <pub-id pub-id-type="doi">10.1111/apt.13299</pub-id>.<pub-id pub-id-type="pmid">26113313</pub-id></mixed-citation></ref><ref id="cit0144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chigutsa</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Wallin</surname><given-names>J</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of necitumumab in cancer patients</article-title>. <source>Clin Pharmacokinet</source>. <year>2017</year>;<volume>56</volume>(<issue>5</issue>):<fpage>505</fpage>&#8211;<lpage>514</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-016-0452-x</pub-id>.<pub-id pub-id-type="pmid">27696220</pub-id><pub-id pub-id-type="pmcid">PMC5385201</pub-id></mixed-citation></ref><ref id="cit0145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sanghavi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Statkevich</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2019</year>;<volume>8</volume>(<issue>12</issue>):<fpage>962</fpage>&#8211;<lpage>970</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12476</pub-id>.<pub-id pub-id-type="pmcid">PMC6930858</pub-id><pub-id pub-id-type="pmid">31710163</pub-id></mixed-citation></ref><ref id="cit0146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gibiansky</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gibiansky</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Carlile</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Jamois</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Buchheit</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Frey</surname><given-names>N</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and Non-Hodgkin&#8217;s lymphoma and exposure&#8211;response in CLL</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2014</year>;<volume>3</volume>(<issue>10</issue>):<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1038/psp.2014.42</pub-id>.<pub-id pub-id-type="pmcid">PMC4474170</pub-id><pub-id pub-id-type="pmid">25353187</pub-id></mixed-citation></ref><ref id="cit0147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Struemper</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sale</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>&#216;stergaard</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>&#214;sterborg</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wierda</surname><given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>Hagenbeek</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Coiffier</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jewell</surname><given-names>RC</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis</article-title>. <source>J Clin Pharmacol</source>. <year>2014</year>;<volume>54</volume>(<issue>7</issue>):<fpage>818</fpage>&#8211;<lpage>827</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.268</pub-id>.<pub-id pub-id-type="pmid">24443277</pub-id></mixed-citation></ref><ref id="cit0148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ewesuedo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>D</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin&#174;) in patients with HER2-positive metastatic breast cancer</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2019</year>;<volume>84</volume>(<issue>1</issue>):<fpage>83</fpage>&#8211;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-019-03850-1</pub-id>.<pub-id pub-id-type="pmid">31053945</pub-id><pub-id pub-id-type="pmcid">PMC6586910</pub-id></mixed-citation></ref><ref id="cit0149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Palaparthy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rehman</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Von Richter</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>D</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis</article-title>. <source>Expert Opin Biol Ther</source>. <year>2019</year>;<volume>19</volume>(<issue>10</issue>):<fpage>1065</fpage>&#8211;<lpage>1074</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14712598.2019.1635583</pub-id>.<pub-id pub-id-type="pmid">31284794</pub-id></mixed-citation></ref><ref id="cit0150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oosterholt</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Della Pasqua</surname><given-names>O</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of raxibacumab in healthy adult subjects</article-title>. <source>Br J Clin Pharmacol</source>. <year>2021</year>;<volume>87</volume>(<issue>12</issue>):<fpage>4718</fpage>&#8211;<lpage>4725</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.14894</pub-id>.<pub-id pub-id-type="pmid">33973655</pub-id></mixed-citation></ref><ref id="cit0151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gota</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Karanam</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rath</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tembhare</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Subramanian</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sengar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nair</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Menon</surname><given-names>H</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of reditux&#8482;, a biosimilar rituximab, in diffuse large B-cell lymphoma</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2016</year>;<volume>78</volume>(<issue>2</issue>):<fpage>353</fpage>&#8211;<lpage>359</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-016-3083-x</pub-id>.<pub-id pub-id-type="pmid">27329361</pub-id></mixed-citation></ref><ref id="cit0152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suleiman</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Minocha</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Khatri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Othman</surname><given-names>AA</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I&#8211;III clinical trials</article-title>. <source>Clin Pharmacokinet</source>. <year>2019</year>;<volume>58</volume>(<issue>10</issue>):<fpage>1309</fpage>&#8211;<lpage>1321</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-019-00759-z</pub-id>.<pub-id pub-id-type="pmid">31054118</pub-id><pub-id pub-id-type="pmcid">PMC6769095</pub-id></mixed-citation></ref><ref id="cit0153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ng</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Combs</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>B</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of rituximab (Anti&#8208;CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial</article-title>. <source>J Clin Pharmacol</source>. <year>2005</year>;<volume>45</volume>(<issue>7</issue>):<fpage>792</fpage>&#8211;<lpage>801</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0091270005277075</pub-id>.<pub-id pub-id-type="pmid">15951469</pub-id></mixed-citation></ref><ref id="cit0154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wenger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Valente</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dmoszynska</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Robak</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mangat</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Visich</surname><given-names>J</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia</article-title>. <source>J Clin Pharmacol</source>. <year>2012</year>;<volume>52</volume>(<issue>12</issue>):<fpage>1918</fpage>&#8211;<lpage>1926</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0091270011430506</pub-id>.<pub-id pub-id-type="pmid">22235140</pub-id></mixed-citation></ref><ref id="cit0155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rozman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grabnar</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Novakovi&#263;</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mrhar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jezer&#353;ek Novakovi&#263;</surname><given-names>B</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of rituximab in patients with diffuse large B&#8208;cell lymphoma and association with clinical outcome</article-title>. <source>Br J Clin Pharmacol</source>. <year>2017</year>;<volume>83</volume>(<issue>8</issue>):<fpage>1782</fpage>&#8211;<lpage>1790</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.13271</pub-id>.<pub-id pub-id-type="pmid">28239897</pub-id><pub-id pub-id-type="pmcid">PMC5510082</pub-id></mixed-citation></ref><ref id="cit0156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Puisset</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>White&#8208;Koning</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kamar</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Huart</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Haberer</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Blasco</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Le Guellec</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lafont</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Grand</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rostaing</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody&#8208;mediated disease</article-title>. <source>Br J Clin Pharmacol</source>. <year>2013</year>;<volume>76</volume>(<issue>5</issue>):<fpage>734</fpage>&#8211;<lpage>740</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.12098</pub-id>.<pub-id pub-id-type="pmid">23432476</pub-id><pub-id pub-id-type="pmcid">PMC3853532</pub-id></mixed-citation></ref><ref id="cit0157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nikanjam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Capparelli</surname><given-names>EV</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of siltuximab: impact of disease state</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2019</year>;<volume>84</volume>(<issue>5</issue>):<fpage>993</fpage>&#8211;<lpage>1001</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-019-03939-7</pub-id>.<pub-id pub-id-type="pmid">31482226</pub-id><pub-id pub-id-type="pmcid">PMC6800650</pub-id></mixed-citation></ref><ref id="cit0158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanzel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bukkems</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Gecse</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Haens</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Math&#244;t</surname><given-names>RAA</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of subcutaneous infliximab CT&#8208;P13 in Crohn&#8217;s disease and ulcerative colitis</article-title>. <source>Alimentary Pharmacol &amp; Ther</source>. <year>2021</year>;<volume>54</volume>(<issue>10</issue>):<fpage>1309</fpage>&#8211;<lpage>1319</lpage>. doi: <pub-id pub-id-type="doi">10.1111/apt.16609</pub-id>.<pub-id pub-id-type="pmcid">PMC9292975</pub-id><pub-id pub-id-type="pmid">34559426</pub-id></mixed-citation></ref><ref id="cit0159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suleiman</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Khatri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Minocha</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Othman</surname><given-names>AA</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn&#8217;s disease: analyses of phase I and II trials</article-title>. <source>Clin Pharmacokinet</source>. <year>2019</year>;<volume>58</volume>(<issue>3</issue>):<fpage>375</fpage>&#8211;<lpage>387</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-018-0704-z</pub-id>.<pub-id pub-id-type="pmid">30123942</pub-id><pub-id pub-id-type="pmcid">PMC6373392</pub-id></mixed-citation></ref><ref id="cit0160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soehoel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Larsen</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Timmermann</surname><given-names>S</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of tralokinumab in adult subjects with moderate to severe atopic dermatitis</article-title>. <source>Clin Pharmacol Drug Dev</source>. <year>2022</year>;<volume>11</volume>(<issue>8</issue>):<fpage>910</fpage>&#8211;<lpage>921</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpdd.1113</pub-id>.<pub-id pub-id-type="pmid">35671038</pub-id><pub-id pub-id-type="pmcid">PMC9796478</pub-id></mixed-citation></ref><ref id="cit0161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Washington</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J-F</given-names></string-name>, <string-name name-style="western"><surname>Lieberman</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Banken</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>P</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2005</year>;<volume>56</volume>(<issue>4</issue>):<fpage>361</fpage>&#8211;<lpage>369</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-005-1026-z</pub-id>.<pub-id pub-id-type="pmid">15868146</pub-id></mixed-citation></ref><ref id="cit0162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Okamoto</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dirks</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Rosario</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hori</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hibi</surname><given-names>T</given-names></string-name></person-group>. <article-title>Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn&#8217;s disease</article-title>. <source>Intest Res</source>. <year>2021</year>;<volume>19</volume>(<issue>1</issue>):<fpage>95</fpage>&#8211;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.5217/ir.2019.09167</pub-id>.<pub-id pub-id-type="pmid">32635680</pub-id><pub-id pub-id-type="pmcid">PMC7873400</pub-id></mixed-citation></ref><ref id="cit0163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rosario</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dirks</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Gastonguay</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Fasanmade</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Wyant</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Parikh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sandborn</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Feagan</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Reinisch</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>I</given-names></string-name>, et al</person-group>. <article-title>Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn&#8217;s disease</article-title>. <source>Alimentary Pharmacol &amp; Ther</source>. <year>2015</year>;<volume>42</volume>(<issue>2</issue>):<fpage>188</fpage>&#8211;<lpage>202</lpage>. doi: <pub-id pub-id-type="doi">10.1111/apt.13243</pub-id>.<pub-id pub-id-type="pmcid">PMC5032981</pub-id><pub-id pub-id-type="pmid">25996351</pub-id></mixed-citation></ref><ref id="cit0164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ng</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Lum</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Gimenez</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kelsey</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Allison</surname><given-names>D</given-names></string-name></person-group>. <article-title>Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis</article-title>. <source>Pharm Res</source>. <year>2006</year>;<volume>23</volume>(<issue>6</issue>):<fpage>1275</fpage>&#8211;<lpage>1284</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11095-006-0205-x</pub-id>.<pub-id pub-id-type="pmid">16715358</pub-id></mixed-citation></ref><ref id="cit0165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ternant</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ducourau</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Perdriger</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Corondan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Le Goff</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Devauchelle&#8208;Pensec</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Solau&#8208;Gervais</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Watier</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Goupille</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Paintaud</surname><given-names>G</given-names></string-name>, et al</person-group>. <article-title>Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis</article-title>. <source>Br J Clin Pharmacol</source>. <year>2014</year>;<volume>78</volume>(<issue>1</issue>):<fpage>118</fpage>&#8211;<lpage>128</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcp.12313</pub-id>.<pub-id pub-id-type="pmid">24354889</pub-id><pub-id pub-id-type="pmcid">PMC4168386</pub-id></mixed-citation></ref><ref id="cit0166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Castro-Su&#225;rez</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Trame</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Ramos-Suzarte</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>D&#225;valos</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Bacallao-Mendez</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Maceo-Sinabele</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Mangas-Sanju&#225;n</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Reynaldo-Fern&#225;ndez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Vera</surname><given-names>L</given-names></string-name></person-group>. <article-title>Semi-mechanistic pharmacokinetic model to guide the dose selection of nimotuzumab in patients with autosomal dominant polycystic kidney disease</article-title>. <source>Pharmaceutics</source>. <year>2020</year>;<volume>12</volume>(<issue>12</issue>):<fpage>1147</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics12121147</pub-id>.<pub-id pub-id-type="pmid">33256255</pub-id><pub-id pub-id-type="pmcid">PMC7760646</pub-id></mixed-citation></ref><ref id="cit0167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodr&#237;guez-Vera</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ramos-Suzarte</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez-S&#225;nchez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Soriano</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Guitart</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez</surname><given-names>GC</given-names></string-name>, <string-name name-style="western"><surname>Jacobo-Cabral</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>de Castro Su&#225;rez</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Codina</surname><given-names>HC</given-names></string-name></person-group>. <article-title>Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer</article-title>. <source>J Clin Pharmacol</source>. <year>2015</year>;<volume>55</volume>(<issue>8</issue>):<fpage>888</fpage>&#8211;<lpage>898</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcph.496</pub-id>.<pub-id pub-id-type="pmid">25760761</pub-id></mixed-citation></ref><ref id="cit0168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Semimechanistically based modeling of pembrolizumab time-varying clearance using 4 longitudinal covariates in patients with non&#8211;small cell lung cancer</article-title>. <source>J Pharm Sci</source>. <year>2019</year>;<volume>108</volume>(<issue>1</issue>):<fpage>692</fpage>&#8211;<lpage>700</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xphs.2018.10.064</pub-id>.<pub-id pub-id-type="pmid">30423341</pub-id></mixed-citation></ref><ref id="cit0169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>XS</given-names></string-name>, <string-name name-style="western"><surname>Moreau</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Usmani</surname><given-names>SZ</given-names></string-name>, <string-name name-style="western"><surname>Lonial</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jakubowiak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oriol</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Krishnan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blad&#233;</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y-N</given-names></string-name>, et al</person-group>. <article-title>Split first dose administration of intravenous daratumumab for the treatment of multiple myeloma (MM): clinical and population pharmacokinetic analyses</article-title>. <source>Adv Ther</source>. <year>2020</year>;<volume>37</volume>(<issue>4</issue>):<fpage>1464</fpage>&#8211;<lpage>1478</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12325-020-01247-8</pub-id>.<pub-id pub-id-type="pmid">32078124</pub-id><pub-id pub-id-type="pmcid">PMC7140755</pub-id></mixed-citation></ref><ref id="cit0170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frank</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kovar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Strougo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vage</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Teuscher</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>N</given-names></string-name></person-group>. <article-title>Sutimlimab pharmacokinetics and pharmacodynamics in patients with cold agglutinin disease</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2023</year>;<volume>386</volume>(<issue>2</issue>):<fpage>143</fpage>&#8211;<lpage>155</lpage>. doi: <pub-id pub-id-type="doi">10.1124/jpet.122.001511</pub-id>.<pub-id pub-id-type="pmid">37164370</pub-id></mixed-citation></ref><ref id="cit0171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Djebli</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Martinez</surname><given-names>J-M</given-names></string-name>, <string-name name-style="western"><surname>Lohan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Khier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brunet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hurbin</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Fabre</surname><given-names>D</given-names></string-name></person-group>. <article-title>Target-mediated drug disposition population pharmacokinetics model of alirocumab in healthy volunteers and patients: pooled analysis of randomized phase I/II/III studies</article-title>. <source>Clin Pharmacokinet</source>. <year>2017</year>;<volume>56</volume>(<issue>10</issue>):<fpage>1155</fpage>&#8211;<lpage>1171</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-016-0505-1</pub-id>.<pub-id pub-id-type="pmid">28063030</pub-id><pub-id pub-id-type="pmcid">PMC5591810</pub-id></mixed-citation></ref><ref id="cit0172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Subramaniam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Blumenthal</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ahamadi</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2017</year>;<volume>44</volume>(<issue>5</issue>):<fpage>403</fpage>&#8211;<lpage>414</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10928-017-9528-y</pub-id>.<pub-id pub-id-type="pmid">28573468</pub-id></mixed-citation></ref><ref id="cit0173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wilkins</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Brockhaus</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Vugmeyster</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Brar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bello</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Neuteboom</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wade</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Girard</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>Time&#8208;varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2019</year>;<volume>8</volume>(<issue>6</issue>):<fpage>415</fpage>&#8211;<lpage>427</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12406</pub-id>.<pub-id pub-id-type="pmcid">PMC6617853</pub-id><pub-id pub-id-type="pmid">30980481</pub-id></mixed-citation></ref><ref id="cit0174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elassaiss-Schaap</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rossenu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lindauer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>de Greef</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sachs</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>de Alwis</surname><given-names>DP</given-names></string-name></person-group>. <article-title>Using model-based &#8220;Learn and confirm&#8221; to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial: modeling of the PK/PD of pembro in KEYNOTE-001</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2017</year>;<volume>6</volume>(<issue>1</issue>):<fpage>21</fpage>&#8211;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12132</pub-id>.<pub-id pub-id-type="pmcid">PMC5270295</pub-id><pub-id pub-id-type="pmid">27863143</pub-id></mixed-citation></ref><ref id="cit0175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aguiar Zdovc</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Han&#382;el</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kurent</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sever</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ko&#382;elj</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smrekar</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Novak</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>&#352;tabuc</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dreesen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>D</given-names></string-name>, et al</person-group>. <article-title>Ustekinumab dosing individualization in Crohn&#8217;s disease guided by a population pharmacokinetic&#8211;pharmacodynamic model</article-title>. <source>Pharmaceutics</source>. <year>2021</year>;<volume>13</volume>(<issue>10</issue>):<fpage>1587</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics13101587</pub-id>.<pub-id pub-id-type="pmid">34683880</pub-id><pub-id pub-id-type="pmcid">PMC8538292</pub-id></mixed-citation></ref><ref id="cit0176"><label>176.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Waldmann</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Strober</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Blaese</surname><given-names>RM</given-names></string-name></person-group>. <part-title>Metabolism of immunoglobulins</part-title>. In: <source>Progress in immunology</source>. <publisher-name>Elsevier</publisher-name>; <year>1971</year>. p. <fpage>891</fpage>&#8211;<lpage>903</lpage>. doi: <pub-id pub-id-type="doi">10.1016/B978-0-12-057550-3.50072-7</pub-id>.</mixed-citation></ref><ref id="cit0177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Terry</surname><given-names>WD</given-names></string-name>, <string-name name-style="western"><surname>Waldmann</surname><given-names>TA</given-names></string-name></person-group>. <article-title>Metabolic properties of IgG subclasses in man</article-title>. <source>J Clin Invest</source>. <year>1970</year>;<volume>49</volume>(<issue>4</issue>):<fpage>673</fpage>&#8211;<lpage>680</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI106279</pub-id>.<pub-id pub-id-type="pmid">5443170</pub-id><pub-id pub-id-type="pmcid">PMC322522</pub-id></mixed-citation></ref><ref id="cit0178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>H&#246;tzel</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Theil</surname><given-names>F-P</given-names></string-name>, <string-name name-style="western"><surname>Bernstein</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Prabhu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Quintana</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lutman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sibia</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bumbaca</surname><given-names>D</given-names></string-name>, et al</person-group>. <article-title>A strategy for risk mitigation of antibodies with fast clearance</article-title>. <source>Mabs-austin</source>. <year>2012</year>;<volume>4</volume>(<issue>6</issue>):<fpage>753</fpage>&#8211;<lpage>760</lpage>. doi: <pub-id pub-id-type="doi">10.4161/mabs.22189</pub-id>.<pub-id pub-id-type="pmcid">PMC3502242</pub-id><pub-id pub-id-type="pmid">23778268</pub-id></mixed-citation></ref><ref id="cit0179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Souders</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Crowley</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Klempner</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>W</given-names></string-name></person-group>. <article-title>A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life</article-title>. <source>Mabs-austin</source>. <year>2015</year>;<volume>7</volume>(<issue>5</issue>):<fpage>912</fpage>&#8211;<lpage>921</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2015.1054585</pub-id>.<pub-id pub-id-type="pmcid">PMC4622054</pub-id><pub-id pub-id-type="pmid">26018774</pub-id></mixed-citation></ref><ref id="cit0180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chung</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>YL</given-names></string-name>, <string-name name-style="western"><surname>Lafrance-Vanasse</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Scales</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sperinde</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>JJ</given-names></string-name>, et al</person-group>. <article-title>An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans</article-title>. <source>Mabs-austin</source>. <year>2019</year>;<volume>11</volume>(<issue>5</issue>):<fpage>942</fpage>&#8211;<lpage>955</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2019.1605270</pub-id>.<pub-id pub-id-type="pmcid">PMC6601550</pub-id><pub-id pub-id-type="pmid">30982394</pub-id></mixed-citation></ref><ref id="cit0181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharma</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Patapoff</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Kabakoff</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hilario</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Borisov</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Chorny</surname><given-names>I</given-names></string-name>, et al</person-group>. <article-title>In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability</article-title>. <source>Proc Natl Acad Sci</source>. <year>2014</year>;<volume>111</volume>(<issue>52</issue>):<fpage>18601</fpage>&#8211;<lpage>18606</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1421779112</pub-id>.<pub-id pub-id-type="pmid">25512516</pub-id><pub-id pub-id-type="pmcid">PMC4284567</pub-id></mixed-citation></ref><ref id="cit0182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bumbaca Yadav</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Boswell</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Hotzel</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Tesar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Grogan</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Chiang</surname><given-names>EY</given-names></string-name>, et al</person-group>. <article-title>Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>(<issue>50</issue>):<fpage>29732</fpage>&#8211;<lpage>29741</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M115.692434</pub-id>.<pub-id pub-id-type="pmid">26491012</pub-id><pub-id pub-id-type="pmcid">PMC4705991</pub-id></mixed-citation></ref><ref id="cit0183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kettenberger</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Richter</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>DK</given-names></string-name></person-group>. <article-title>Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies</article-title>. <source>Mabs-austin</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>1993769</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2021.1993769</pub-id>.<pub-id pub-id-type="pmcid">PMC8565835</pub-id><pub-id pub-id-type="pmid">34711143</pub-id></mixed-citation></ref><ref id="cit0184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brinkhaus</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pannecoucke</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>van der Kooi</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Bentlage</surname><given-names>AEH</given-names></string-name>, <string-name name-style="western"><surname>Derksen</surname><given-names>NIL</given-names></string-name>, <string-name name-style="western"><surname>Andries</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Balbino</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sips</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ulrichts</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Verheesen</surname><given-names>P</given-names></string-name>, et al</person-group>. <article-title>The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement</article-title>. <source>Nat Commun</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>6073</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-022-33764-1</pub-id>.<pub-id pub-id-type="pmid">36241613</pub-id><pub-id pub-id-type="pmcid">PMC9568614</pub-id></mixed-citation></ref><ref id="cit0185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Volkov</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brinkhaus</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>van Schie</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Bondt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kissel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>van der Kooi</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Bentlage</surname><given-names>AEH</given-names></string-name>, <string-name name-style="western"><surname>Koeleman</surname><given-names>CAM</given-names></string-name>, <string-name name-style="western"><surname>de Taeye</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Derksen</surname><given-names>NI</given-names></string-name>, et al</person-group>. <article-title>IgG Fab glycans hinder FcRn-mediated placental transport</article-title>. <source>J Immunol</source>. <year>2023</year>;<volume>210</volume>(<issue>2</issue>):<fpage>158</fpage>&#8211;<lpage>167</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.2200438</pub-id>.<pub-id pub-id-type="pmid">36480251</pub-id></mixed-citation></ref><ref id="cit0186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Korth-Bradley</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Rubin</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Simcoe</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Lebsack</surname><given-names>ME</given-names></string-name></person-group>. <article-title>The pharmacokinetics of etanercept in healthy volunteers</article-title>. <source>Ann Pharmacother</source>. <year>2000</year>;<volume>34</volume>(<issue>2</issue>):<fpage>161</fpage>&#8211;<lpage>164</lpage>. doi: <pub-id pub-id-type="doi">10.1345/aph.19126</pub-id>.<pub-id pub-id-type="pmid">10676822</pub-id></mixed-citation></ref><ref id="cit0187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haraya</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tachibana</surname><given-names>T</given-names></string-name></person-group>. <article-title>Estimation of clearance and bioavailability of therapeutic monoclonal antibodies from only subcutaneous injection data in humans based on comprehensive analysis of clinical data</article-title>. <source>Clin Pharmacokinet</source>. <year>2021</year>;<volume>60</volume>(<issue>10</issue>):<fpage>1325</fpage>&#8211;<lpage>1334</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-021-01023-z</pub-id>.<pub-id pub-id-type="pmid">33954956</pub-id><pub-id pub-id-type="pmcid">PMC8505369</pub-id></mixed-citation></ref><ref id="cit0188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mullenix</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Koren</surname><given-names>E</given-names></string-name></person-group>. <article-title>An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen</article-title>. <source>J Immunological Methods</source>. <year>2005</year>;<volume>304</volume>(<issue>1&#8211;2</issue>):<fpage>189</fpage>&#8211;<lpage>195</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jim.2005.06.014</pub-id>.<pub-id pub-id-type="pmid">16107258</pub-id></mixed-citation></ref><ref id="cit0189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rane</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Donahue</surname><given-names>PMC</given-names></string-name>, <string-name name-style="western"><surname>Towse</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ridner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chappell</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jordi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gore</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Donahue</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Clinical feasibility of noninvasive visualization of lymphatic flow with principles of spin labeling MR Imaging: implications for lymphedema assessment</article-title>. <source>Radiology</source>. <year>2013</year>;<volume>269</volume>(<issue>3</issue>):<fpage>893</fpage>&#8211;<lpage>902</lpage>. doi: <pub-id pub-id-type="doi">10.1148/radiol.13120145</pub-id>.<pub-id pub-id-type="pmid">23864103</pub-id><pub-id pub-id-type="pmcid">PMC4485559</pub-id></mixed-citation></ref><ref id="cit0190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Van Valkengoed</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Krekels</surname><given-names>EHJ</given-names></string-name>, <string-name name-style="western"><surname>Knibbe</surname><given-names>CAJ</given-names></string-name></person-group>. <article-title>All you need to know about allometric scaling: an integrative review on the theoretical basis, empirical evidence, and application in human pharmacology</article-title>. <source>Clin Pharmacokinet</source>. <year>2025</year>;<volume>64</volume>(<issue>2</issue>):<fpage>173</fpage>&#8211;<lpage>192</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40262-024-01444-6</pub-id>.<pub-id pub-id-type="pmid">39644458</pub-id><pub-id pub-id-type="pmcid">PMC11782306</pub-id></mixed-citation></ref><ref id="cit0191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Argyrakopoulou</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Fountouli</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dalamaga</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kokkinos</surname><given-names>A</given-names></string-name></person-group>. <article-title>Revisiting resting metabolic rate: what is the relation to weight fluctuations?</article-title><source>Curr Obes Rep</source>. <year>2023</year>;<volume>12</volume>(<issue>4</issue>):<fpage>502</fpage>&#8211;<lpage>513</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13679-023-00528-x</pub-id>.<pub-id pub-id-type="pmid">37755607</pub-id></mixed-citation></ref><ref id="cit0192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hendrikx</surname><given-names>JJMA</given-names></string-name>, <string-name name-style="western"><surname>Haanen</surname><given-names>JBAG</given-names></string-name>, <string-name name-style="western"><surname>Voest</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Schellens</surname><given-names>JHM</given-names></string-name>, <string-name name-style="western"><surname>Huitema</surname><given-names>ADR</given-names></string-name>, <string-name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></string-name></person-group>. <article-title>Fixed dosing of monoclonal antibodies in oncology</article-title>. <source>Oncologist</source>. <year>2017</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1212</fpage>&#8211;<lpage>1221</lpage>. doi: <pub-id pub-id-type="doi">10.1634/theoncologist.2017-0167</pub-id>.<pub-id pub-id-type="pmid">28754722</pub-id><pub-id pub-id-type="pmcid">PMC5634778</pub-id></mixed-citation></ref><ref id="cit0193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boer</surname><given-names>P</given-names></string-name></person-group>. <article-title>Estimated lean body mass as an index for normalization of body fluid volumes in humans</article-title>. <source>Am J Physiol-Ren Physiol</source>. <year>1984</year>;<volume>247</volume>(<issue>4</issue>):<fpage>F632</fpage>&#8211;<lpage>F636</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajprenal.1984.247.4.F632</pub-id>.<pub-id pub-id-type="pmid">6496691</pub-id></mixed-citation></ref><ref id="cit0194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kantasiripitak</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Outtier</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wicha</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Kensert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Sabino</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vermeire</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ferrante</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dreesen</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Multi&#8208;model averaging improves the performance of model&#8208;guided infliximab dosing in patients with inflammatory bowel diseases</article-title>. <source>CPT Pharmacomet Syst Pharmacol</source>. <year>2022</year>;<volume>11</volume>(<issue>8</issue>):<fpage>1045</fpage>&#8211;<lpage>1059</lpage>. doi: <pub-id pub-id-type="doi">10.1002/psp4.12813</pub-id>.<pub-id pub-id-type="pmcid">PMC9381887</pub-id><pub-id pub-id-type="pmid">35706358</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>